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ABSTRACT OF THE DISSERTATION
The Roles of Plasmepsins IX and X in Malaria Parasite Biology
by
Armiyaw Sebastian Nasamu
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Microbiology and Microbial Pathogenesis
Washington University in St. Louis, 2021
Professor Daniel E. Goldberg, Chair
Proteases of the malaria parasite Plasmodium falciparum have been targeted for drug discovery
for decades. The P. falciparum genome encodes ten aspartic proteases called plasmepsins, which
are involved in diverse cellular processes. In this work we address the roles of two of these
plasmepsins, plasmepsins IX and X (PM IX and X), the two least studied aspartic proteases in
blood stage malaria parasites till date. We explore the essentiality of these proteases in parasite
development, attempt to identify their substrates and the ability to drug them. We show that PM
IX is essential for erythrocyte invasion, acting on rhoptry secretory organelle biogenesis.
When PM IX is knocked down, rhoptry formation is impaired but the substrate (s) of PM IX
responsible for this phenotype have not yet been discovered.

viii

We have suspected targets and the progress made on implicating these important substrates will
be reported in this work.
In contrast, PM X is essential for both egress and invasion, controlling maturation of the
subtilisin-like serine protease SUB1 in exoneme secretory vesicles. SUB1, synthesized as a
zymogen needs to be converted to its active form after an initial self-cleavage. We explored the
mechanism by which PM X converts the intermediate SUB1 species to its active form.
Interestingly, we discover that PM X cleaves the intramolecular self-inhibiting prodomain part of
the protein probably allowing a second activation step. We proceed to determine the cleavage
sites that could prevent the inhibitory function of the prodomain. We have identified compounds
with potent antimalarial activity targeting PM X, including a compound known to have oral
efficacy in a mouse malaria model.

ix

Preface
In this thesis work, I will present novel findings on two aspartic proteases in the malaria parasite
Plasmodium falciparum, called plasmepsins IX and X.
First, in chapter one, I will introduce malaria, the life cycle of P. falciparum, the current state of
knowledge all the known aspartic proteases in the malaria parasite including the 10 plasmepsins,
and the other aspartic proteases. For each of these, the mysteries that remain will be questioned.
In chapter 2, I will tell you the functions of plasmepsins IX and X. At the start of the project,
nothing was known about either protease. The only evidence of their expression in red blood
cell stage parasites was the presence of mRNA in transcriptomic experiments, albeit at very low
levels and an immunofluorescence signal from fixed cells. The aims for the project are listed
here. They apply to both proteases.
1. Determining if they are essential for parasite survival
2. Determining their localization
3. Determining their substrates
4. Investigating the mechanisms by which they cleave their substrates and
5. Finding inhibitors that block their function and kill parasites
We show that they are both expressed in late stage parasites and are essential for egress and
invasion. We localize them and identify some substrates as well as inhibitors for PM X.
After that, in chapter 3, I will discuss one of the mysteries of PM X, namely how it cleaves the
substrate we identified and how that cleavage is novel.
In chapter 4, I will discuss the discoveries we have made and what remains to be learned about
this PM IX and X.
In the appendix, I reference a collaboration with my co-graduate student Alex J. Polino showing
our discovery of the role of PM V. I then show data for one of the predicted substrates of PM IX.
We will show that it is required in parasites and that the cleavage is important. We will question
if PM IX is responsible for the cleavage.

x

CHAPTER 1

Malaria parasite plasmepsins: More than just plain old degradative pepsins
Armiyaw S. Nasamu*, Alexander J. Polino*, Eva S. Istvan and Daniel E. Goldberg#
Washington University School of Medicine Division of Infectious Diseases, Department of
Medicine and Department of Molecular Microbiology St Louis, MO 63110

Running title: Malaria Parasite Plasmepsins
#To whom correspondence should be addressed: Daniel E. Goldberg, dgoldberg@wustl.edu,
314-362- 1514
Keywords: aspartic protease, parasitology, Plasmodium, protozoan, hemoglobin, maturase,
malaria, digestive vacuole, transmission, antimalarial chemotherapy

Notes: This worked was published in the Journal of Biological Chemistry in 2020. I wrote the
parts on invasion and egress as well plasmepsins VI-III which are only found in sexual stages
and studied mostly in rodent malaria. My co-first author A.J.P constructed the phylogenetic trees
for the plasmepsins and wrote the chapter on Plasmepsin V. EI and D.E.G contributed to the rest
of the paper.

1.1 ABSTRACT
Plasmepsins are a group of diverse aspartic proteases in the malaria parasite Plasmodium. Their
functions are strikingly multifaceted, ranging from hemoglobin degradation to secretory
organelle protein processing for egress, invasion and effector export. Some, particularly the
digestive vacuole plasmepsins, have been extensively characterized whereas others, such as the
transmission-stage plasmepsins, are minimally understood. Some (e.g., plasmepsin V) have
exquisite cleavage sequence specificity; others are fairly promiscuous. Some have canonical
pepsin-like aspartic protease features, while others have unusual attributes, including the
nepenthesin loop of plasmepsin V and a histidine in place of a catalytic aspartate in plasmepsin
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III. We have learned much about the functioning of these enzymes but more remains to be
discovered about their cellular roles and even their mechanisms of action. Their importance in
many key aspects of parasite biology makes them intriguing targets for antimalarial
chemotherapy. Further consideration of their characteristics suggests that some are more viable
drug targets than others. Indeed, inhibitors of invasion and egress offer hope for a desperately
needed new drug to combat this nefarious organism.

1.2 INTRODUCTION
Malaria is caused by protozoan organisms of the genus Plasmodium. The disease is transmitted
by infected female Anopheles mosquitos, which inject salivary gland sporozoites into the skin
during blood feeding. These sporozoites make their way to the liver, replicate and differentiate
into infective merozoites. The merozoites egress into the bloodstream, where they invade red
blood cells (RBCs) and set up a continuous intraerythrocytic cycle that amplifies their
population, often to overwhelming numbers. Some differentiate into sexual stage parasites, to be
taken up by the next mosquito and develop in the mosquito midgut, ultimately migrating to the
salivary glands for spread to a new victim (Figure 1.1)

Aspartic proteases called plasmepsins (Plasmodium pepsins, abbreviated PM) play important
roles in each stage of Plasmodium development. Interest in the plasmepsins began when the
digestive vacuole plasmepsins (I, II, III and IV) were found to be important for intraerythrocytic
hemoglobin degradation (1–5). There followed a major effort to make small molecule inhibitors
to these enzymes, especially PM II, the easiest to express and the first to have a crystal structure
(6, 7). A poor correlation between ability of a compound to kill parasites and potency against
isolated enzyme (8) suggested that digestive vacuole plasmepsin inhibition was not the mode of
parasite killing for these molecules. This ultimately led to the realization that there must be other
targets, likely other aspartic proteases, whose inhibition is responsible for the antiplasmodial
properties. The search for these targets has uncovered myriad functions for these enzymes.
Plasmepsins are involved in bulk protein degradation, secretory protein maturation, egress,
invasion, endothelial adherence and perhaps other processes. A number have been the subject of
2

serious efforts as targets for drug development. Plasmepsins (Figure 2) belong to an ancient
family of aspartic proteases—the A1 or pepsinlike family—that is widespread throughout
eukaryotes. Among the ten plasmepsins, the most closely related are the digestive vacuolar
plasmepsins, PM I-IV. These proteases are spread across just 16 kilobases of chromosome 14
and share 50-70% amino acid identity. Outside of P. falciparum and related primate-infecting
species, these proteases are represented by a single plasmepsin, called PM IV in Plasmodium and
ASP1 in the related apicomplexan Toxoplasma gondii (9). PM V is the most diverged
plasmepsin, sharing 19-23% amino acid identity with the other plasmepsins. Its structure is
bolstered by seven disulfide bonds (compared to two in PM I-IV), bringing it into a separate
aspartic protease subfamily from the other plasmepsins—subfamily A1B, with type member
Nep1 of the pitcher plant Nepenthesia (10). Other apicomplexans also have a single PM V
ortholog (Asp5 in Toxoplasma gondii), except for cryptosporidia, which have three (9).
Regarding transmission-stage plasmepsins, PM VI and VIII form a clade, sharing 36% amino
acid identity with each other. Each has a little-studied ortholog in T. gondii (ASP2 and ASP4
respectively). PM VII has distant homology to PM VI and VIII (31% identity); its
uncharacterized Toxoplasma ortholog is ASP6. PM IX and PM X share 37% amino acid identity.
Although the two are distinct across Plasmodium and exist on different chromosomes, they are
represented by a single T. gondii aspartic protease, ASP3.
A note on nomenclature: In the literature, plasmepsins are denoted with Roman numerals or
Arabic numerals, with a space before the number or without, and plasmepsin III is known as
histoaspartic protease or HAP or PM III (or PMIII or PM3 or PM 3). We suggest going back to a
convention initiated in early publications of having Roman numerals after a space. We further
suggest that HAP be referred to as PM III for consistency with the other plasmepsins and
because its His34 has not been shown to be catalytic. Also, HAP is the name for a gamete fusion
protein. Using PM III allows the digestive vacuole plasmepsins in aggregate to be called PM IIV without ambiguity. An argument for the space before the Roman numeral is that PM V is
often referred to in discussions of sending proteins out to the parasitophorous vacuolar
membrane or PVM, and PMV gets confusing in this context. These issues are ultimately for
those concerned with nomenclature to weigh in on, but in this review we will use our preferred
convention. There are also non-plasmepsin aspartic proteases in the Plasmodium genome (see
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Other Aspartic Proteases). The microgametocyte surface protein (MiGS) has homology to PM V
(21% amino acid identity and shared transmembrane domain; 17- 20% to other plasmepsins).
Additional aspartic proteases in the Plasmodium genome—signal peptide peptidase (SPP) and
DNA damageinducible 1 (Ddi1)—are quite distinct from the plasmepsins. SPP is a presenilintype aspartic protease (family A22). Ddi1 (family A28) is the most diverged from the other
aspartic proteases. It possesses a single catalytic aspartate, and likely homodimerizes to complete
the active site, an unusual architecture among eukaryotic aspartic proteases (though common to
retroviral aspartic proteases). Here we review the state of knowledge on the plasmepsins, noting
outstanding questions in the field. This review will focus on Plasmodium falciparum, the
deadliest human malaria parasite, for which extensive biological studies have been performed;
reference to other species will be made as relevant. Study of the diverse plasmepsins has taught
us much about the biology of the malaria parasite, a little about the protein chemistry of aspartic
proteases, and is pointing the way to exciting new inhibitors that are being developed as
antimalarial chemotherapeutic agents.

1.3 DIGESTIVE VACUOLE PLASMEPSINS: PLASMEPSINS I-IV
Intraerythrocytic malaria parasites digest hemoglobin at a prodigious rate (11). This catabolic
process provides nutrients for the parasite and has been proposed to maintain osmotic balance in
the host cell (11–13). Hemoglobin is ingested by Plasmodium through an endocytic structure
called the cytostome, which spans the plasma membrane and the vacuolar membrane
surrounding the parasite (Figure 3A) (14, 15). Hemoglobin-containing vesicles pinch off and
fuse with the digestive vacuole, an acidic organelle containing 10 proteases that function in a
semi-ordered pathway to degrade the hemoglobin to small peptides and amino acids (16–18)
(Figure 3B). Some of these peptides are thought to be exported out of the digestive vacuole for
terminal degradation in the cytoplasm (17, 19, 20). The degradative process may start in
transport vesicles and commences early after erythrocyte invasion (14). Heme is liberated by
degradation and most is sequestered as a crystalline lattice of beta-hematin dimers called
hemozoin (21). Some antimalarial drugs like chloroquine appear to function by blocking heme
sequestration, leading to toxic heme build-up (22). A network of proteins implicated in the
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hemoglobin endocytosis process has recently been defined, and includes the artemisininresistance protein.

DISCOVERY
Involvement of aspartic proteases in hemoglobin digestion was suspected nearly 50 years ago
from the characterization of crude parasite extracts (25, 26). The older literature contains
numerous reports of hemoglobin-degrading acidic protease activities in various Plasmodium
species and some were shown to be blocked by the canonical aspartic protease inhibitor pepstatin
A (25–34). Their cellular roles remained unclear until studies on isolated digestive vacuoles
showed the ability to degrade hemoglobin (16, 35) and protease inhibitor profiling of
hemoglobinase activity from highly purified digestive vacuoles revealed a central role for
aspartic proteases (16). Soon thereafter, two aspartic proteases (now called PM I and II) were
purified from large-scale digestive vacuole preps and shown to cleave hemoglobin (1, 2, 36).
After release of the P. falciparum genome, two more plasmepsins were shown to be present in
the digestive vacuole, PM III and PM IV (4, 5, 37).

FUNCTION
There is extensive functional redundancy among the digestive vacuole plasmepsins, and
between these enzymes and the cysteine proteases called falcipains. Knockouts of individual P.
falciparum plasmepsins have minor effects on parasite growth in culture (38–41), while
knockout of all four leads to a substantial growth defect, though the knockout line is still viable
(42). Knockout of the single P. berghei digestive vacuole plasmepsin yields a similar phenotype
in the mouse model (43, 44). Cysteine protease inhibitors are more potent in the P. falciparum
knockouts (38, 42), and knockouts of falcipain-2 are more sensitive to aspartic protease
inhibitors (45), highlighting the redundancy between the two digestive vacuole protease families.
Plasmepsins and falcipains are synergistic in biochemical assays of hemoglobin degradation (16,
36, 46) and cysteine/aspartic protease inhibitor synergism is observed in culture (47, 48). as well
as in a rodent malaria model (48). A final level of redundancy is that digestive vacuole
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plasmepsins are activated by falcipains, but if the falcipains are impaired, plasmepsins can
autoactivate (49) (see below). Further proteolysis of globin fragments by the metalloprotease
falcilysin (50, 51), the dipeptidylaminopeptidase DPAP1 (52), aminopeptidase P (53) and
aminopeptidase M1 (54) finish the degradation process (Figure 3).
The digestive vacuole plasmepsins have been proposed to be in a complex with some of the
downstream proteases as well as with a heme detoxification protein (HDP) in the digestive
vacuole (55). Curiously, recent reports have associated amplification of PM II and PM III with
resistance to the antimalarial drug piperaquine in several lineages of Southeast Asian field
isolates (56–58) Removal of these extra copies of PM II/PM III resensitized parasites to
piperaquine, suggesting this amplification contributes to the resistance phenotype (58).
Additionally, deletion of PM II or PM III from a laboratory P. falciparum strain sensitized
parasites to piperaquine in vitro (59) However, increasing PM II/PM III levels is not sufficient to
impart piperaquine resistance in laboratory strains, hinting at a more complex picture where
interplay between PM II/PM III levels and other constituents of a strain’s genetic background
contributes to phenotypic resistance (60). Consistent with this, polymorphisms in the digestive
vacuolar membrane transporter PfCRT are sufficient to impart piperaquine resistance in vitro,
and parasite lines with these PfCRT mutations naturally lose PM II/PM III amplification while
retaining piperaquine resistance in culture (61).
STRUCTURE AND MECHANISM
The structures of all four P. falciparum digestive vacuole plasmepsins and the singleton PM IV
from several other species have been elucidated (7, 62–68). Each has the typical bilobal
pepsinfamily aspartic protease fold. These plasmepsins are capable of forming dimers in
crystalline form and in solution (69, 70), though it is the monomer that has been shown to be
active. The PM III dimer has a loop from one of the subunits that intrudes into the second
subunit active site, where it coordinates a zinc ion via Asp215 and His32 (71). The canonical
Asp215-Thr218 hydrogen bond is disrupted by the zinc coordination. PM I, II and IV appear to
function as typical aspartic proteases, with their two aspartates participating in acid-base
catalytic activation of a water molecule through a tetrahedral transition state (72), but in contrast,
the mechanism of PM III (Figure 4A) is not fully understood (66). In PM III, Asp215 appears to
function as a catalytic base, activating the water to form the hydrolytic nucleophile (67). It is not
6

clear whether His 32 is involved in catalysis. It could be the catalytic acid for resolution of the
tetrahedral intermediate typical of aspartic protease action, in analogy to the standard aspartate in
this position. The positioning of the statine hydroxyl between Asp 215 and His32 in the
transition-state inhibitor pepstatin-bound structure is supportive of this concept (67). A His32Ala
mutant of recombinant PM III retained activity, however (73). It has been suggested that PM III
could be a serine protease, using Ser35 as the nucleophile (74), but a Ser35Ala mutant retained
activity (73) and the pepstatin active site interactions in the structure look more consistent with
an aspartic protease mechanism (67). Concerning the possibility that it could be a zinc
metalloprotease, native enzyme was not inhibited by EDTA (5) and only the dimeric apoenzyme
structure had active site zinc (67), while it is the monomer that is active (70). A proposal was put
forth that Asp215 acts as an acid as well as a base, but this model was based on a profound
stabilization (several orders of magnitude) by His32 (75). Perhaps a different residue could be
the stabilizer; Lys78 has been suggested (73). Weighing on this debate is the fact that the
properties of native enzyme and the recombinant enzyme used for mutagenesis studies are very
different. PM III was originally isolated from digestive vacuoles, had a sharp pH optimum of 5.5,
and was well inhibited by pepstatin (5). Three different isolation procedures gave similar results
and there was no detectable contamination by other plasmepsins (though trace contamination by
a plasmepsin or another protease cannot be completely excluded). Recombinant protein
expressed in E. coli had similar properties (76). Later, recombinant protein was again expressed
in E. coli for analysis of site-directed mutants mentioned above, but had a broad pH optimum
from 5 to 8.5, was poorly inhibited by pepstatin, and was potently inhibited by PMSF (73). A
His215Ala mutant had no activity, but the Ser35Ala and His32Ala mutants were similar to wild
type.
It is hard to reconcile these later results with the earlier data, unless there was a contaminating
activity present in some of the samples, perhaps from the enterokinase used to generate mature
recombinant enzyme. The existing data do not yet form a coherent picture of the mechanism of
action of this unusual aspartic protease ortholog.
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SPECIFICITY
An extensive series of studies has assessed specificity of cleavage of hemoglobin or synthetic
peptides using native and recombinant digestive vacuole plasmepsins. The four P. falciparum
enzymes and the single enzyme from the three other human parasite species (P. ovale, P. vivax,
P. malariae) as well as enzyme from the rodent species P. berghei and P. chabaudi have been
studied (4, 5, 84–90, 6, 77–83). All four P. falciparum enzymes are capable of degrading
hemoglobin and function at the acidic pH of the digestive vacuole (5). Other degradative
proteases such as cathepsin E are not able to degrade native hemoglobin, so this is a special
property of the digestive vacuole plasmepsins (91). There are minor differences between species,
but activity on synthetic peptide libraries shows a general preference for large hydrophobic
residues proximal to the cleavage site on the P (N-terminal) and P’ (C-terminal) sides, especially
at the P1 and P3 positions, with somewhat broader tolerance at P1’ and P3’ and wide latitude at
P2 and P2’. On native hemoglobin, time course studies using native PM I and PM II revealed an
initial cleavage of hemoglobin (a 2 b 2 tetramer) on the a chain between Phe33 and Leu34 (1,
36). Proteolysis proceeded with cleavages at a number of sites on both chains. Specificity of
cleavage correlated well with the data just mentioned for synthetic peptides. Experiments using
peptides corresponding to the scissile a-helix (helix B) revealed enhanced cleavage by PM II
when the helix was extended N-terminally and could then interact with a loop on the PM II
molecule (91). A model was put forth wherein the plasmepsin recognizes the beginning of the B
helix on the a chain of hemoglobin and perches, waiting for the helix to breathe. The B helix is
the weakest link on the protein because it has two helix-disrupting glycines. The protease is in
position to cleave the 33-34 peptide bond as soon as the helix opens, helping unravel the tightly
wound hemoglobin molecule so that further proteolysis can proceed (Figure 4B).
BIOSYNTHESIS
Biosynthesis of digestive vacuole plasmepsins follows a circuitous route. The enzymes are made
as transmembrane zymogens that traverse the secretory system, reach the parasite surface, are
internalized via the cytostome along with their substrate hemoglobin, get delivered to the
digestive vacuole membrane, and are then cleaved, releasing the mature enzyme into the
vacuolar lumen (92–94) (Figure 3C). Maturation is carried out by the digestive vacuole cysteine
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proteases falcipain-2 and 3 (49). If those enzymes are inhibited, plasmepsin autoprocessing takes
place, albeit at a slower rate and at a site one amino acid upstream from the normal cleavage site.
Structures of P. falciparum PM II, PM III, and PM IV proenzymes as well as those of P. vivax
PM IV have been solved (63, 95–97). The proenzyme of each is inactive because the propiece
pushes apart the N- and C-terminal lobes of the protease, keeping the catalytic residues too far
apart for activity. This differs from mammalian aspartic protease zymogens, for which the
propiece binds to the substrate cleft to maintain inactivity until pH-dependent autoactivation can
take place.
KEY QUESTIONS
What is the mechanism of PM III? Is His32 involved in catalysis? Is PM III even an active
enzyme? -Systems biology of hemoglobin degradation: how do cleavages made by each
plasmepsin and by other proteases synergize? Why maintain four plasmepsins in P. falciparum?
Why do some parasites amplify the digestive vacuole plasmepsin gene region even further? When is heme released during hemoglobin proteolysis and how is this orchestrated with
hemozoin formation?

1.4. EFFECTOR PROTEIN EXPORT: PLASMEPSIN V
After invasion, the parasite exports hundreds of proteins into the host RBC. These exported
effectors enact a dramatic program of host modification, reconstituting a complex trafficking
system in the RBC cytosol and altering the host cell’s rigidity, nutrient permeability, and
endothelial binding properties (98, 99). A significant portion of this export program appears
dedicated to trafficking families of variable membrane adhesins to the RBC surface, creating
adhesin-rich protrusions called “knobs” that mediate binding to the vascular endothelium (Figure
5) (100). In P. falciparum, around 400 predicted gene products are annotated as likely to be
exported (101, 102). Nearly 200 belong to three families of membrane adhesins (~120 rifins, 50
PfEMP1s and 30 stevors) (101, 103). Many of the remaining predicted proteins have no clear
function, and no homology to genes outside Plasmodium. We are still just beginning to
understand the mechanisms by which Plasmodium manipulates its host through its exported
proteins.
9

DISCOVERY
Initial evidence of aspartic proteases acting on processes other than hemoglobin degradation
came nearly two decades ago, when antibodies raised against newly annotated aspartic proteases
labeled parasites outside the digestive vacuole (104). PM V was characterized as a constitutively
expressed ER-resident integral membrane protein (105). In 2004, the Haldar and Cowman
groups independently discovered that many proteins destined for export contain a pentameric
amino acid motif approximately 15-30 amino acids downstream from the signal sequence,
termed the Plasmodium export element (PEXEL) with the consensus sequence RxLxE/Q/D (106,
107). This element was shown to be necessary and sufficient to export fluorescent reporters. In
2008, Chang et al. reported that exported proteins are cleaved in the ER, after the conserved Leu
in the PEXEL sequence (108). The advent of tools for reverse genetics in P. falciparum enabled
the assignment of the PEXEL-processing function to PM V (109, 110). Development of
peptidomimetic inhibitors of PM V has driven further discovery, validating PM V as essential for
parasite survival in RBCs during the asexual cycle and gametocytogenesis (111–113) In addition
to uncovering novel parasite biology, these inhibitors have enabled the determination of a highresolution PM V structure, opening the door to biochemical and pharmacological investigation of
this essential enzyme (114). A number of tools have now been turned towards the study of PM V
including inducible Di-Cre excision (115) and posttranscriptional depletion (111, 116, 117), as
well as expression, purification and activity assessment in PM V expressed from E. coli (110,
118–121), insect cells (114), and in parasite culture (109, 110), enabling rapid progress in our
knowledge of this enzyme, and its development as a potential antimalarial target.

FUNCTION
PEXEL-containing proteins are translated into the ER, immediately processed by PM V after the
PEXEL Leu, then acetylated at the new N-terminus by an unknown N-acetyltransferase (108–
110, 122, 123). Preventing PEXEL processing by mutating PEXEL or depleting/inhibiting PM V
blocks protein export, indicating that PM V serves as a gatekeeper for the export pathway (106,
107, 111, 117). Processed PEXEL proteins are secreted into the parasitophorous vacuole, then
exported across the vacuolar membrane into the host cell via the Plasmodium translocon for

10

exported proteins (PTEX) (124–127) (Figure 5). A number of proteins lack PEXEL yet are still
exported, termed PEXEL-negative exported proteins (PNEPs). Their N-termini are believed to
confer export competency similarly to that of the mature PEXEL N-terminus (128). Most known
PNEPs are involved in trafficking adhesins to the RBC surface or are adhesins themselves. PM V
is not the only gatekeeper to protein export; several mutated PEXEL reporters are correctly
cleaved by PM V but still retained in the parasitophorous vacuole (101, 123). Two nonmutuallyexclusive models have been put forward to explain this. First, export-destined proteins may
contain trafficking information in addition to PEXEL that targets them for export. This
information would have to be C-terminal to PEXEL, as N-terminal sequence is removed by PM
V. Exported reporter studies have greatly limited the possible locations of such information. The
N-terminus of PEXEL proteins, containing the PEXEL motif followed by just 11 amino acids,
supports export of a GFP fusion (106, 107). Following PEXEL cleavage, the only detectable
sequence conservation is the P2’ residue (largely restricted to Gln, Glu, or Asp). Residues
beyond P2’ are important for export, as an inserted PEXEL was not sufficient to re-target the
normally vacuole-resident SERA5 to the RBC, but if the subsequent 18 amino acids from the
PEXEL protein PfEMP3 were added, export was restored (101). However, the properties of these
sequences that support export have remained elusive; they have no obvious conserved sequence,
structure, or biochemical properties; and Boddey, et al. (101) reported the surprising finding that
even replacing the postP2’ amino acids with all Ala supports protein export, leaving us to
wonder what signaling information this sequence could contain. A variant of this model would
be that secreted proteins bind HSP101 and get exported by default, unless they are too tightly
folded (129) or contain an N-terminal sequence that prevents chaperone recognition. The second
model posits that following PEXEL cleavage, PM V hands off export-destined cargo to an ER
chaperone that ushers it through the export pathway (109). In this model, PM V is required not
just for cleavage, but also for some downstream step. Tests of this model were attempted with
constructs that would create a post-PEXEL N-terminus independent of PM V using either an
engineered signal peptidase or a fused viral protease; these gave discordant results, with the
signal peptidase-generated N-terminus unable to support export, while the viral proteasegenerated N-terminus did support export (110, 130). Another avenue for elucidating the post-PM
V path is to determine its interacting partners, a task that was carefully undertaken by Danushka,
et al. (131). They found that PM V interacts with a noncatalytic component of the signal
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peptidase complex SPC25 and, if cross-linked, with the ER translocon Sec61, its accessory
proteins for posttranslational import Sec62/63, as well as signal peptidase. They posited that
secretory proteins follow one of two distinct paths: either they are cleaved by the canonical
signal peptidase complex, or they are recognized and cleaved by a distinct signal processing
complex consisting of PM V and SPC25 (131) (Figure 6). Perhaps there are chaperones that
recognize this complex selectively, though their identity is not apparent at this time. A variant of
the chaperone hand-off model is that PM V could be in a subregion of the ER with a direct route
to the PTEX translocon at the PVM (110, 132). Subregions of the PVM have recently been
described, with each region hosting distinct secretory proteins (133, 134). However, there is no
information yet about whether these PVM subregions are fed by distinct regions of the ER.
There is some evidence that PM V additionally functions as a secretory maturase for dense
granule proteins. Dense granules are small secretory vesicles that discharge shortly after parasite
invasion into the parasitophorous vacuole surrounding the parasite. In addition to the canonical
PEXEL, PM V cleaves the “relaxed PEXEL” (RxLxxE) of the dense granule protein RESA (101,
117). Following PEXEL cleavage, RESA is diverted to the dense granules of the forming
daughter merozoites. When these merozoites re-invade new RBCs, RESA is secreted into the
vacuolar lumen and rapidly exported via PTEX into the host cell (124, 125). Inhibition of PM V
shortly before egress is rapidly deleterious in newly invaded ring-stage parasites (117). RESA
itself is non-essential, and whether PM V cleaves additional dense granule proteins is not yet
clear. In Toxoplasma gondii, the PM V ortholog ASP5 cleaves dense granule proteins at a
PEXEL-like motif (135–137). When ASP5 processing is blocked, substrates still traffic to the
dense granules, but are unable to fulfill their roles in modifying the parasitophorous vacuole or
host cell (136). If PM V does act as a dense granule protein maturase in both Toxoplasma and
Plasmodium, perhaps this is its ancestral function, a concept that would be especially interesting
given recent findings on the translocon, PTEX.
This complex is made up of three core components: a AAA+-ATPase Hsp101, a channelforming protein Exp2, and an adaptor protein PTEX150 (126). Hsp101 is a ubiquitous chaperone
that has been co-opted by Plasmodium to unfold and thread proteins through the translocon.
Exp2, in Plasmodium and Toxoplasma, forms a nutrient pore to get essential substances such as
glucose and amino acids from the host cell (138, 139). This protein has also been deployed by
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Plasmodium for a second function— protein export. To dock Hsp101 to the Exp2 pore for
protein export, the organism has come up with a novel adapter PTEX150 (127). Thus, we
suggest that Plasmodium has cobbled together a protein export system from mostly pre-existing
components and further, it has recruited another pre-existing protein, PM V, to prepare proteins
for export. It is not at all clear why most exported proteins need to be made as pre-proteins and
processed by PM V co-translationally unless the cleavage motif (PEXEL) is an important
component of the export recognition system.
SPECIFICITY
Unlike the digestive vacuole proteases, PM V has a highly specific recognition sequence,
cleaving only after the conserved Leu of the consensus PEXEL sequence RxLxE/Q/D (108, 122,
123). Mutation of the highly conserved PEXEL residues P1 or P3 ablate cleavage (with the
notable exception of P1 Ile, which can inconsistently support some PMV cleavage) (101, 106,
107, 140). PM V does not cleave the PNEPs SBP1, PfEMP1, and REX2 (101), or a fluorogenic
globin-derived peptide cleaved by PM I-IV (105). Functional PEXELs are found 15 to 30 amino
acids downstream of the signal sequence (141); however, whether this location is required for
PM V cleavage has not been reported.
STRUCTURE
The structure of the P. vivax PM V bound to a peptidomimetic inhibitor has been determined and
reveals that PM V largely resembles the digestive vacuole plasmepsins, with a few notable
differences (114) (Figure 7). Like PM IIV, PM V is produced with a poorly conserved Nterminal extension speculated to be a selfinhibiting prodomain. However, processing of PM V
has not been detected (105) and the fulllength recombinant protein has been reported to be active
(118, 119). As in other plasmepsins, the PM V active site is covered by a flap that may serve to
regulate substrate access. The PM V flap is several amino acids longer than the analogous region
of the digestive vacuole plasmepsins, a difference that could perhaps underlie PM V’s unique
substrate specificity. Along the flap (but not predicted to contact the substrate) is an unpaired
Cys, which has been implicated in PM V’s sensitivity to Hg2+ (118, 120, 121). Connected
directly to the flap is an insert made up of two cysteine pairs folded into a cloverleaflike structure
called a “nepenthesin insert”, which it shares with Nep1 from the pitcher plant Nepenthesia. The

13

nepenthesin insert is present in PM V across the genus, but absent from other plasmepsins. Its
location adjoined to the flap over the active site tempts us to speculate that the nepenthesin insert
may respond to some environmental condition or binding partner and regulate access to the
active site. Alternatively, the nepenthesin insert could be a set distance from the active site and
be involved in measuring distance from the N-end of potential substrates (142). No clear hint
comes from its ortholog Nep1, a broad-substrate digestive protease present in the low pH of the
pitcher plant lumen (143).
Another unusual feature is a helix-turnhelix motif, again not present in other plasmepsins. While
this is often a nucleic acidinteracting motif, it is not clear what purpose such a motif might have
in the ER lumen, where all but the non-essential C-terminal tail of PM V is found (109, 144).
Projecting away from the active site of the enzyme is a poorly structured insert whose length and
sequence varies among different Plasmodium species and isolates from different regions (145,
146); mutagenesis studies on recombinant enzyme have not yet revealed a function for this
structure (146). Further work has the potential to both uncover novel parasite biology, but also to
unearth secrets of biochemistry broadly applicable to other enzymes outside of Plasmodium.
KEY QUESTIONS
What do signature features of PM V do (helix-turn-helix motif, nepenthesin loop, unpaired
cysteine in the flap)? -What is the basis of exported protein targeting and how is PM V involved?
Is N-acetylation a required part of this and is it coordinated with PM V action? -What are the
essential PM V substrates required for parasitophorous vacuole establishment?
1.5 TRANSMISSION-STAGE PLASMEPSINS
PLASMEPSINS VI, VII AND VIII (PM VI, VII and VIII) are expressed only in transmissionstage parasites, and have roles in midgut sporozoite development and function (104). They have
been studied mostly in the rodent malaria parasite P. berghei, where each has been disrupted
with no effect in the RBC cycle. PM VI knockout parasites produce oocysts that fail to develop
into sporozoites, resulting in a transmission block (147). PM VII can be detected in the
cytoplasm of P. falciparum zygotes and ookinetes, but its function is not known (148). The
protein is not present in P. falciparum gametocytes, suggesting that it is produced after
fertilization. Knock out has no effect on any stage of the P. berghei life cycle (149). PM VIII
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knockout parasites form oocysts in the mosquito midgut (150). However, there is a drastic
decrease in the number of salivary gland and hemolymph sporozoites when PM VIII is absent,
due to a defect in egress from oocysts. The few sporozoites produced have a defect in gliding
motility. Consequently, transmission of these parasites to the host is blocked. The egress
phenotype mirrors that seen with PM X in intraerythrocytic parasites (see below), but
mechanistic details for PM VIII function remain to be elucidated. More work is needed to
understand the function of these important enzymes.
KEY QUESTIONS
What are the specific roles and substrates of these proteases? Do the inhibitors being developed
against other plasmepsins also target the transmission-stage plasmepsins? What is the role of
other plasmepsins such as PM X in the transmission stages?
1.6 EGRESS/INVASION PLASMEPSINS: PLASMEPSINS IX AND X
An obvious consequence of the malaria parasite’s intraerythrocytic lifestyle is that it needs to
get into the host cell and, when it is finished replicating and dividing, needs to get back out
(Figure 8A). Invasion is a multistep process (151, 152) involving initial low-affinity recognition
of the red blood cell by the parasite, re-orientation of the invasive merozoite and discharge of
secretory organelles. This allows high-affinity binding to erythrocyte surface proteins and to
parasite proteins that the organism has secreted onto the host cell membrane. This is followed by
erythrocyte cytoskeletal reorganization and signaling cascades, tight junction formation, actinmediated entry and finally resealing once inside. The whole invasion process takes less than a
minute. Egress is also a complex phenomenon (153–155). The parasite must porate and disrupt
the surrounding parasitophorous vacuolar membrane, disassemble the host cell cytoskeleton,
porate and finally rupture the erythrocyte membrane, which it does explosively, releasing new
infective merozoites into the circulation. The egress process takes about ten minutes. Proteases
play key roles in egress and invasion; in invasion, proteolytic processing is essential for invasion
protein function; in egress there is a proteolytic cascade, triggered by the cGMP-dependent
discharge of proteases into the parasitophorous vacuole (154). Recent evidence suggests that
aspartic proteases play important roles in both entry and exit from the erythrocyte.
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PM IX is expressed in late-stage schizonts and is localized to rhoptries (Figure 8B), secretory
organelles that contain adhesins for erythrocyte invasion and proteins for setting up the PVM
upon invasion (156). This organelle is highly segregated, with the invasion ligands at the apical
end (neck) and other proteins at the basal end (bulb). Upon depletion/disruption of P. falciparum
PM IX, invasion of red blood cells is severely compromised (156, 157). Depletion/disruption of
PM IX also blocks cleavage of the rhoptry-associated protein 1 (RAP1) and the apical sushi
protein (ASP). Peptides corresponding to the cleavage sites of both proteins are cleaved by
recombinant PM IX. The activity was observed at pH 6.4 (157). RON3, a rhoptry protein
inserted into the PVM during or just after invasion, is also thought to be a PM IX substrate from
inhibitor studies (158). Rhoptry morphogenesis and attachment defects were observed in the PM
IX-depleted strain (156). These defects presumably explain the invasion phenotype observed.
The substrates of PM IX responsible for the phenotype are still not known since RAP1 is not
essential (159) and ASP is predicted to be non-essential by a piggy bac transposon mutagenesis
screen (160). Maturation of PM IX appears to be auto-catalytic (158).
PM X is involved in both egress and invasion (156–158). In asexual P. falciparum parasites, PM
X is localized to small oval-shaped vesicles called exonemes (156). The other protein that has
been localized to this organelle is the serine protease subtilisin-like protease 1 (SUB1). PM X
processes SUB1 in order to activate it. Knockdown or chemical inhibition of PM X results in the
accumulation of SUB1 precursor (156–158). Mature SUB1 is required for the degradation of
both the parasitophorous vacuole and red cell membranes to allow dissemination of merozoites
from a mother schizont. To initiate the egress cascade, SUB1 activates cysteine proteases called
SERAs and merozoite surface proteins called MSPs (154). Full block of PM X traps parasites
within the PVM, while partial block allows egress from this membrane but prevents escape from
the RBC membrane. Presumably a higher level of activated SUB1 is required for its effects on
the erythrocyte. PM X also processes the surface adhesin sheddase SUB2, as well as erythrocyte
binding-like (EBL) and Rh family members that are all involved in invasion (158). In sexual
stages of P. falciparum, PM X is expressed in gametes, zygotes, and ookinetes and in P. berghei,
is implicated by inhibitor studies in egress from gametocytes and mosquito midgut invasion
(148, 157). PM X processes the midgut invasion protein Celltraversal protein for ookinetes and
sporozoites (CelTOS) (157). Inhibitors also prevent progression from the liver to erythrocytes,
though different compounds either block merosome formation, hence egress of schizonts in
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hepatocytes (157), or have an effect on merozoite competence (158). It is worth noting that
compounds used in these studies inhibit both PM IX and PM X. PM IX is not expressed in liver
or sexual stages, however, suggesting that action may be specific to PM X in these portions of
the life cycle, though some effects through action on another aspartic protease may be suggested
by the fact that different small molecules have been reported to have somewhat different effects
on mosquito and liver-stage parasites. Recombinant PM X is active at pH 5.5 and can cleave a
variety of synthetic peptide substrates, including ones based on SUB1, EBA-175, EBA181 and
Rh2 (156–158). It has a strong preference for cleavage between two hydrophobic residues, not
dissimilar from the digestive vacuole plasmepsins, and prefers a polar P2 residue and Glu, Gln or
Asp for P2’ (158). PM X can cleave PM IX substrates, suggesting overlapping specificity (158).
PM X is autocatalytic but in parasites not all the PM X gets processed; they retain some as
proenzyme (66 kDa) or as active 51 and 44 kDa versions (156–158). An ER calcium-binding
protein called PfERC is required for PM X maturation in an unknown fashion (161). In
Toxoplasma gondii, one aspartic protease called ASP3 is closely related to both PM IX and PM
X (9). It is localized in an endosomal compartment (post-Golgi). This protein processes
microneme and rhoptry proteins and is implicated in egress and invasion and hence is thought of
as a PM IX and PM X chimera (162). Mutations in the conserved Phe344 confer resistance to the
small molecule inhibitor 49c in cultured Toxoplasma and for isolated ASP3, PM IX or PM X
(163). The cleavage sites for ASP3 substrates are similar to the peptide cleavage sites for the PM
IX and PM X that were tested, adding to the concept of their relatedness and similar roles in the
two organisms. PM V, IX and X all share a function as secretory organelle protein maturases
(Figure 8B).
KEY QUESTIONS -What are the key substrates of PM IX required for rhoptry morphogenesis?
How does PM X cleave and activate the SUB1 precursor that is bound to its propiece? -Where
does PM X interact with and process some microneme and rhoptry proteins? It has only been
found in exonemes thus far.
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1.7 OTHER ASPARTIC PROTEASES
Four other putative aspartic proteases are encoded in the Plasmodium genome but were not
appreciated when the plasmepsins were named (164). One, called MiGS (microgametocyte
surface protein), is most homologous to PM V but is expressed in male gametocytes and
microgametes (165, 166). It appears to play a role in formation of the secretory osmiophilic
bodies of male gametocytes. After secretion onto the surface, it also plays a role in exflagellation
of male microgametes that go on to fertilize the female gametes. Like the other plasmepsins, it is
predicted to have a classical pepsin-like fold; however, one of the catalytic sites has clearly
undergone substantial mutation, with the conserved DTGS mutated to LTNS. Whether MiGS
folds in an unexpected way to bring another catalytic residue into the active site, acts as a
homodimer, or acts as a pseudoprotease is unclear. Ddi1 (DNA damage-inducible protease 1) is
another aspartic protease with a Plasmodium ortholog. In other eukaryotes, it is important for the
cell cycle through ubiquitin/proteasome interactions (167). It has only one catalytic aspartate and
homodimerizes to form the active enzyme.
In malaria parasites, all that is known is that its gene is refractory to knockout in P. berghei and
P. falciparum (160, 168, 169). SPP (signal peptide peptidase) is an intramembrane aspartic
protease that processes signal peptides after release from secretory proteins in the ER. Early
reports based on antibody and inhibitor studies suggested that the Plasmodium ortholog of SPP
might be a micronemal protein involved in invasion (170, 171). Further reports, however, instead
localized this protein to the ER and demonstrated roles in signal peptide proteolysis and ER
stress responses (172–174). More detailed cellular analysis of SPP-selective inhibitor treatment
showed inhibition of intraerythrocytic parasite development rather than invasion (172).
Heterologous expression studies have confirmed the ability to cleave intramembrane signal
peptides (173, 175, 176). Potent SPP inhibitors that kill cultured intraerythrocytic parasites (171–
173, 177) and also block liver stage development (173, 178) have been described. SPP appears to
be an attractive drug target. Finally, a gene present on chromosome 14 (PF3D7_1465600) next to
PM VIII and annotated as an aspartic protease (164), has very distant homology to PM VIII but
the predicted protein is missing both catalytic motifs and is unlikely to be an active protease. It is
expressed most highly in male gametocytes and may also be expressed in asexual parasites and
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other life cycle stages (179). The gene is predicted to be essential in P. falciparum but not in P.
berghei from genomescale mutational analyses (160, 168). Its function is completely unknown.
KEY QUESTIONS
How does MiGS work in exflagellation? Is it an active enzyme? What are its substrates? -What
is the role of Ddi1 in the parasite? What are associated proteins and substrates? -Can selective
SPP inhibitors be developed? What is the role of SPP in the ER stress response? PLASMEPSINS
1.8 AS DRUG TARGETS
Thousands of inhibitors have been designed against plasmepsins. Additionally, clinically used
HIV protease inhibitors such as lopinavir have been investigated in detail, though their clinical
antimalarial efficacy is likely to be marginal. The inhibitor literature has been reviewed
elsewhere (8, 180, 181) and is beyond the scope of this article. Here, we will instead focus on
implications of the biology of plasmepsins for drug development. Digestive vacuole plasmepsins
play an important role in hemoglobin degradation. Knockout lines are markedly impaired in
growth both in culture
(P. falciparum) (42) and in vivo (P. berghei rodent model) (43, 44). In fact, the attenuated P.
berghei are cleared and can protect from subsequent challenge with heterologous parasites. That
being said, knockout parasites are still viable and an anti-digestive vacuole plasmepsin drug
would need a very long half-life to suppress growth over multiple cycles for parasite clearance. It
is unlikely that a digestive vacuole plasmepsin-specific agent will come to fruition, though a
compound that blocked digestive vacuole plasmepsins in addition to an essential plasmepsin
(CWHM-117 is an example (156)) would likely get an efficacy boost from its action on
hemoglobin degradation. PM V is another interesting enzyme to consider as a target. The process
of protein export is essential (124, 125, 138), as presumably is dense granule secretion that helps
form the parasitophorous vacuole after invasion, in which PM V likely plays a role (117).
Blocking PM V could potentially hit the parasite at two different points in its developmental
cycle, which is an advantage for treating an infection that can be asynchronous. Tempering
enthusiasm for this target is the observation that PM V must be knocked down nearly completely
to have any effect on parasite viability. The implication is that a drug would have to have
exceptional potency to be effective. Current recommended EC50 values for parasite killing by
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candidate compounds are in the low nanomolar range. A compound would likely have to have a
mid-picomolar ki for PM V to achieve efficacy. Not impossible, but a very high bar. Plasmepsin
VI, VII and VIII are potential drug targets for insect stages of the parasite. A drug against an
enzyme in these stages would not cure a patient but could prevent transmission of the disease.
Dosing patients to get a curative concentration in the mosquito is a potential hurdle. Not enough
is known about these enzymes to have a clear idea how to move forward. PM VII appears to be
dispensable, and therefore would be low on the list. PM IX is a candidate drug target. It is
essential for blood-stage parasites (156, 157) and is inhibited by the small molecule inhibitors
49cand WM382 (157, 158), though both compounds are also potent against PM X. PM X is also
essential for blood-stage parasites and can be potently blocked by the dual inhibitory compounds
mentioned above, as well as by aminohydantoins (156–158). Each of these chemotypes is active
in vivo using rodent malaria models and 49c and WM382 also have been shown to interrupt
transmission to mosquitos as well as egress from hepatocytes. The extraerythrocytic phenotypes
are likely due to a block of PM X, though an important role for the inhibition of other
plasmepsins such as PM VIVIII cannot be excluded. Dual inhibition of PM IX and X, or PM X
and an insect-stage PM would be a bonus for an antimalarial because of heightened difficulty in
selecting resistance or ability to treat more than one stage (157, 158). However, keeping a drug
development program on-target for two different enzymes while avoiding inhibition of host
orthologs such as cathepsin D is a challenging task (182, 183). Inhibition of PM X may be
enough to hit multiple life cycle stages by itself. Drug development for PM X is proceeding at a
rapid pace (158, 184).
KEY QUESTIONS
HIV protease inhibitors like lopinavir kill malaria parasites in culture. What is their killing
target? The digestive vacuole plasmepsins, Ddi1, SPP, and hexose transporter PfHT1 have all
been proposed (169, 185–189). -Do PM X inhibitors work in mosquito stages by blocking PM X
and/or do they target other enzymes such as MiGS or PM VI-VIII? -Will a drug against a target
that is active during just a few hours of the life cycle show sustained efficacy? -Is hemoglobin
digestion a viable target?
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1.9 CONCLUSIONS
Plasmepsins participate throughout the complex biology of the malaria parasite (Table 1.1). The
digestive vacuole plasmepsins are the most extensively studied, and we have a reasonable picture
of their biosynthesis and roles in hemoglobin degradation. We do not yet understand the
mechanism of PM III, with its histidine instead of a canonical aspartate.
Plasmepsin V is the next best-studied plasmepsin. Its role in exported effector protein processing
is fairly clear, but its function in dense granule protein processing is not well established. The
protein has a number of unusual domains whose functions are not clear at this time. Plasmepsins
VI-VIII as well as the PM V paralog MiGS, play roles in the insect stages; PM X may as well.
Studies of these protease activities in the mosquito are just beginning. PM IX and PM X have
defined roles in erythrocytic invasion and egress, but their enzymology is not yet defined. Many
of these enzymes afford opportunities for antimalarial drug discovery and we can look forward to
exciting new drug candidates in the not too distant future.
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Figure 1. Life cycle of the malaria parasite. Sporozoites from the salivary glands of an infected
mosquito (bottom) make their way to the liver (yellow), infect hepatocytes, replicate to thousands of
infective merozoites and bud off as merosomes that rupture into the bloodstream. The merozoites
invade RBCs, replicate and multiply in the intraerythrocytic cycle (red). Some differentiate into male
and female gametocytes that are taken up into the mosquito, where they develop (blue). In the
mosquito midgut, parasites egress from the RBCs as gametes, mate to form zygotes, and differentiate
into ookinetes that traverse the midgut and become oocysts. They replicate and differentiate into
sporozoites that migrate to the salivary glands, where they are ready for transmission to the next
human upon mosquito bite. Roman numerals designate plasmepsins that are thought to function at a
specific point in the life cycle.
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Figure 2. Plasmepsin phylogeny. Distance bar represents 0.1 amino acid substitutions per site. Sequences

for PMs I-X were obtained from PlasmoDB (release 46), aligned using MUSCLE ("Multiple
Sequence Comparison by Log-Expectation", EMBL,
citation https://www.ncbi.nlm.nih.gov/pubmed/15034147), and visualized using iTOL (interactive
tree of life, reference https://pubmed.ncbi.nlm.nih.gov/30931475/).
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Figure 3. Hemoglobin ingestion and digestion. A. Electron micrograph of a P. falciparum-infected
erythrocyte. RBC, red blood cell; C, cytostome; V, vesicle; DV, digestive vacuole. From ref 16. B.
Semi-ordered pathway of hemoglobin degradation. Plasmepsins and falcipains are involved in the initial steps
of catabolism and are partially redundant. Falcilysin recognizes oligopeptides. Dipeptidyl aminopeptidase 1
(DPAP1) cleaves two residues off of the N-terminus of hemoglobin fragments. Aminopeptidases finish the
digestion, resulting in free amino acids. Heme is liberated during the initial steps of proteolysis; most is
sequestered in the digestive vacuole as hemozoin. C. Plasmepsin targeting pathway follows the hemoglobin
internalization route. Plasmepsins are made in the ER and traverse the secretory system as type II integral
membrane protein precursors (stick and ball). They traffic to the cytostome, a hemoglobin ingestion apparatus
that spans the two membranes at the parasite surface. They are internalized with their substrate cargo
(hemoglobin) and are delivered to the digestive vacuole (DV) surface, where they are cleaved by falcipain-2
(FP-2). Black bars are the hemozoin crystals that accumulate after heme release.
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Figure 4. A. Crystal structure of PM III complexed with pepstatin. Ribbon structure
(blue) with Asp215 and His32 highlighted in yellow with red and blue heteroatoms.
Pepstatin is in green with red oxygens. Figure constructed from PDB 3FNT. B.
Crystal structure of PM II (blue) with the B helix of the hemoglobin alpha chain
modeled in orange. Alpha 33-34 cleavage site is green; helix-interacting loop is
magenta. PDB 1PSE.
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Figure 5. Biosynthesis and trafficking of exported proteins. Proteins are synthesized in the endoplasmic
reticulum (ER), traverse the secretory system (green) to the parasitophorous vacuole (PV, blue), where
they are recognized by the PTEX translocon and exported into the RBC (pink). In the RBC, effectors can
be soluble, can reside in the Golgi-like Maurer’s clefts (MC) that are established by the parasite in the
host cell, can be vesicular (V) or can go to the RBC surface, forming nutrient acquisition channels (PSAC)
or clustering variant surface cytoadhesins in knobs at the RBC surface.
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Figure 6. Model for signal processing in the ER. Secretory proteins are cleaved immediately after
translation either by the canonical signal peptidase (SPC21) complex (left) or a non-canonical PM V
processing complex (right). NAT- putative N-acetyltransferase.
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Figure 7 –Crystal structure of PM V with the inhibitor WEHI-842 bound (green). Highlighted are the
flap over the active site (magenta), nepenthesin loop (yellow, with Cys-Cys bonds in red), and helixturn-helix (orange). From PDB 4ZL4.

A

R = rhoptry
DG = dense granule
G = Golgi apparatus
ER = endoplasmic reticulum

M = microneme
E = exoneme
N = nucleus

Figure 8 . Plasmodium invasion and egress. A. An infective merozoite (top left) attaches to an
RBC, reorients so that its apical end is in contact with the host cell, and invades. It
develops,replicates and divides, forming a schizont (bottom right). When ready to egress, it
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disrupts thePVM, then the RBC membrane and finally merozoites rupture out of the RBC
explosively (bottom left). B. Schematic of a merozoite, showing secretory organelles whose
function is influenced by plasmepsins. Exonemes discharge to initiate egress. Then micronemes
discharge to secrete RBC adhesion ligands onto the cell surface. Next rhoptries discharge to
prepare parasite and host cell for invasion and to condition the PVM. Finally, dense granules
discharge to effect maturation of the parasitophorous vacuole

Table 1.1. Plasmodium aspartic proteases: temporal and spatial location and function. IE, infected
erythrocyte.
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2.1 ABSTRACT
Proteases of the malaria parasite Plasmodium falciparum have long been investigated as drug
targets. The P. falciparum genome encodes ten aspartic proteases called plasmepsins, which are
involved in diverse cellular processes. Most have been studied extensively but the functions of
plasmepsins IX and X (PM IX and X) were unknown. Here, we show that PM IX is essential for
erythrocyte invasion, acting on rhoptry secretory organelle biogenesis. In contrast, PM X is
essential for both egress and invasion, controlling maturation of the subtilisin-like serine protease
SUB1 in exoneme secretory vesicles. We have identified compounds with potent antimalarial
activity targeting PM X, including a compound known to have oral efficacy in a mouse malaria
model.
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2.2 MAIN TEXT
Considerable work has gone into synthesis of plasmepsin inhibitors as antimalarials (1-4). Most
efforts have been directed at the digestive vacuole plasmepsins, PMI-IV because of the
availability of crystal structures and recombinant proteins. However, genetic knockouts reveal
that these are not essential for parasite survival (5). Thus, rationally designed inhibitors of PMIIV likely exert their antimalarial effects through other targets (1, 3). PMV, IX and X are the only
other plasmepsins expressed in asexual blood stage parasites (6). PMV is an essential protease
that processes proteins for export into the host erythrocyte and is a focus of ongoing drug
development efforts (7-9). PMV is, however, quite divergent from the other plasmepsins (10)
and most digestive vacuole plasmepsin inhibitors are not potent against this enzyme (11). PMIIV share more sequence homology to PM IX and X (10). PM IX and X could be the targets of
PMI-IV inhibitors that have antimalarial activity.
To characterize the functions of PM IX and X in the biology of blood-stage P. falciparum
parasites, we used new TetR-aptamer conditional knockdown (KD) technology (12) (Fig. S1),
enabling translational repression of the target gene when anhydrotetracycline (aTc) is removed
from the culture. Using CRISPR/Cas9 editing, we installed the TetR-aptamer regulatory system
at the PM IX and X loci to create PM IXapt and PM Xapt lines (Fig. S1). When aTc levels were
lowered in synchronous, early ring-stage parasites we observed a major decrease in target protein
levels in late-stage schizonts, in both PM IXapt and PM Xapt (Fig. 1A). This decreased replication,
revealing a critical role for both of these enzymes in parasite survival (Fig. 1B).
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To determine the stage at which the defect occurred, cell-cycle progression was monitored using
highly synchronous ring-stage parasites cultured under knockdown (-aTc) or induced (+aTc)
conditions. Flow cytometry revealed that both PM IXapt and PM Xapt developed normally until
they reached segmented schizonts (~44 h). At the end of the cycle (between 46-52 h), similar
numbers of PM IXapt schizonts had egressed irrespective of PM IX expression status. However,
there were ~4-fold fewer new rings in –aTc cultures (Fig. 1C). A similar 4-fold decrease was
seen in -aTc PM Xapt cultures (Fig. 1D). Unlike for PM IXapt, at 52 h, 80% of PM Xapt parasites
had egressed in +aTc cultures while only 36% had egressed in –aTc cultures. Even taking the
egress defect into account, however, we observed fewer rings than expected, indicating an
additional invasion phenotype. We further characterized this by live microscopy of individual
cells (13) (Fig. 1E) and observed similar egress and invasion impairment (Fig. 1F). Unruptured
schizonts accumulated in the –aTc culture as merozoite clusters and some distorted schizonts;
occasionally these partially ruptured or displayed defective merozoite dispersal (Fig. 1G). Of the
parasites that could egress in a normal time frame under –aTc conditions, the merozoite invasion
rate was ~50% of that observed +aTc (Fig 1F). These data implicate PM IX in erythrocyte
invasion and PM X in both egress and invasion. A PM IXapt/Xapt double aptamer-tagged line
displayed a similar defect in egress and a greater block in invasion, yielding ~7-fold fewer rings
(Fig. S2). This implies independent contributions of PM IX and X to these processes.

To evaluate the subcellular localization of these proteins, we engineered epitope tags on the 3’
end of the endogenous genes (Fig. S3) and performed immunoelectron microscopy. PM IX was
found largely in the bulbs of rhoptry secretory organelles that are involved in invasion (14) (Fig.
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2A, B). PM X was found in exonemes- small, ovoid secretory vesicles that discharge during
egress into the parasitophorous vacuole surrounding the parasite (15) (Fig. 2C-E).
The localization studies guided us to examine organellar proteins whose processing could be
affected by PM action. RAP1 is a rhoptry bulb protein that is processed from an 84 kDa
precursor to 82 kDa and 67 kDa forms. The PM IXapt line failed to process the precursor
efficiently when aTc was withdrawn (Fig. 3A). In contrast, the rhoptry neck protein RON4 was
processed despite PM IX knockdown. By electron microscopy, a rhoptry biogenesis defect was
evident under knockdown conditions (Fig. 2F, G).
The subtilisin-like serine protease SUB1 is an exonemal protein that plays a critical role in egress
and invasion (15, 16). SUB1 is synthesized as an 82kDa zymogen that rapidly self-processes
into a 54kDa semi-pro-enzyme in the ER. The cleaved prodomain remains bound to the 54kDa
protein and inhibits activity (17). A second processing step converts the 54kDa form into a
47kDa mature protein. This step can occur autocatalytically in vitro, but is slow and partial (18,
19). A processing enzyme has been postulated for this step (20) but its identity is unclear.
Strikingly, a major defect in SUB1 processing was observed in PM Xapt (Fig. 3B) but not PM
IXapt (Fig. S4) after aTc withdrawal, indicating that PM X is important for the final SUB1
processing step. Consistent with this, PM X is synthesized and rapidly processed shortly before
SUB1 synthesis and processing occurs (Fig. 3C). Similar to the second processing step of SUB1,
PM X maturation is blocked by brefeldin A (Fig. S5), suggesting a post-ER event.
During egress, SUB1 processes a family of cysteine proteases (SERAs) and a family of
merozoite surface proteins (MSPs) (15, 16). SERA5 is synthesized as a 126 kDa protein and is
processed sequentially by SUB1 into 73 kDa and 56 kDa forms. The latter is further processed
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into a 50kDa fragment in a SUB1-independent process (21). We assessed SERA5 in PM Xapt
parasites. In the absence of aTc, SERA5 accumulated in the 126 kDa form with very little
processing to other intermediates (Fig. 3D). Similarly, MSP1 accumulated as its 193 kDa
precursor (Fig. S6). Thus, PM X knockdown impairs downstream egress events.
We tested whether PM X is an active protease by introducing an ectopic gene copy (Fig. 3E, F,
Fig. S7). PM Xapt parasites constitutively expressing a second copy PM X gene with an active
site aspartate mutation (D266G), had reduced growth in the absence of aTc and were unable to
restore processing of SUB1. In contrast, those expressing a wild-type second copy gene were
rescued. These data show that PM X enzymatic activity in vivo is crucial to its function.
Interestingly, the catalytic mutant PM X was processed to the mature form, suggesting a transprocessing event (Fig. S7B).
Many aspartic protease inhibitors with antimalarial properties have been investigated but the
specific targets for most of them are unknown (1). Three aminohydantoins were identified
(TCMD-134675 and TCMD-136879 from the TCAMS collection (22) and CWHM-117 (11)),
that led to schizont accumulation reminiscent of our PM Xapt phenotype. To determine if these
compounds act in a PM IX or X-dependent manner, dose-response curves were determined for
KD parasites. The half-maximal effective concentration (EC50) values were substantially lower
for PM Xapt but not PM IXapt cultured in low aTc (Fig 4A, B). This indicates hypersensitivity of
PM Xapt parasites to aminohydantoins when PM X expression is low. Egress and invasion were
blocked and an accumulation of abnormal schizonts was observed by live-cell microscopy for
CWHM-117 (Fig. 4C, D). Further, treatment of parasites with each of these inhibitors blocked
SUB1 and SERA5 maturation (Fig. 4E), as was seen with PM X KD. Treatment with
aminohydantoins did not block the initial SUB1 autoprocessing step. The compounds also did
57

not inhibit PM X maturation (Fig. 4E). Recombinant PM X cleaved a fluorogenic peptide as well
as SUB1 protein in vitro and these reactions were blocked by aminohydantoins (Fig. 4F, S9),
with IC50 values from 175 to 800 nM in the peptide assay. Combining PM X KD and inhibitor
treatment resulted in a complete block of egress and SUB1 maturation (Fig. 4G, H). As CWHM117 has oral efficacy in a mouse model (11), it appears PM X is a promising target for
antimalarial chemotherapy.
We have determined that PM IX and X are essential for parasite egress and invasion. PM IX
localizes to the rhoptries and could be a maturase for proteins in this organelle. We have
discovered that PM X is required for SUB1 processing, making PM X the most upstream
protease known in the egress cascade (Fig. 4I). However, it is not clear that the final cleavage of
SUB1 is a direct action of PM X, and if it is, it could result from processing of semi-pro SUB1 or
from cleavage of the prodomain, liberating semi-pro SUB1 to process itself. PM X is capable of
cleaving SUB1 in vitro (Fig. S9), adding support to the direct cleavage model.
PM X does not appear to autoprocess (Fig. 4E, Fig. S7B) unlike most aspartic proteases,
suggesting that there may be another maturase upstream in the proteolytic cascade of egress yet
to be discovered. We have identified compounds with a common scaffold that are specific
inhibitors of PM X and recapitulate the actions of PM X knockdown phenotypically. Our PM IX
and X lines should allow high-throughput screening of aspartic protease inhibitor collections and
may inform efforts to improve on the promising CWHM-117 lead compound.
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2.4 FIGURES

Fig. 1. PM IX is essential for invasion of erythrocytes; PM X is essential for egress and invasion.
(A) Immunoblot with αFlag antibody showing knockdown of PM IX and PM X after aTc
withdrawal for one cycle. Haloacid dehalogenase-like hydrolase (HAD1): loading control. (B)
Expansion of PM IXapt and PM Xapt parasites is impaired in –aTc medium (p<.0001 for each by
two-tail t-test). Triangles, PM IXapt; circles, PM Xapt. Open symbols, -aTc; closed symbols, +aTc.
(C, D) PM IX knockdown results in an invasion defect. PM X knockdown results in both egress
and invasion defects. Synchronized ring-stage cultures were grown ±aTc. Schizonts and rings
were counted by flow cytometry at 44 and 52 hrs post-invasion (hpi). Shaded bars, schizonts;
open bars, rings. (C) 52 hr rings decreased in –aTc condition p<.0001 (t-test); schizonts NS. (D)
52 hr rings decreased in –aTc p<.0001; schizonts increased p<.001. (E-G) Live-cell microscopy
of PM X parasites ±aTc. (E) Individual schizonts were scored for egress and subsequent invasion
(arrows in image of control parasite field). (F) Quantification of PM Xapt egress and invasion
defects –aTc. ***p<.001. (G) Abnormal schizont classes observed following PM X KD: (1)
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distorted schizont, (2) unruptured merozoite cluster and (3) defective egress/merozoite dispersal.
(4) Normal schizont for comparison. Bar= 5 um. All experiments in this and subsequent figures
were replicated at least 3 times. +aTc 1uM.

Fig. 2. PM IX localizes to rhoptries while PM X localizes to exonemes. (A, B) The PM IX gene
was tagged with 3X HA at the 3’ end of the endogenous open reading frame. Tagged parasites
grew normally. Segmented schizonts were prepared for immunoEM, and PM IX was visualized
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with anti-HA antibody and 18 nm colloidal gold-labeled secondary antibody. Co-localization
with anti-RAP1 antibody, a marker for rhoptries, was performed using 12 nm colloidal goldlabeled secondary antibody. Arrowhead points to 18 nm particle; arrow points to 12 nm particle.
(A) schizont; (B) merozoite. (C, D) The PM X gene was HA-tagged and visualized as for PM IX.
Box from schizont (C) enlarged in (D). (E) The PM X gene was tagged with GFP and the
exoneme marker SUB1 was tagged with 3x HA. Segmented schizonts were prepared for
immunoEM and PM X was visualized with anti-GFP antibody and 18 nm colloidal gold-labeled
secondary antibody; SUB1 was visualized with anti-HA antibody and 12 nm colloidal goldlabeled secondary antibody. Two examples are shown. Controls omitting primary antibody were
negative in all cases. (F, G) Electron micrographs of PM IXapt cultured +aTc (F) or –aTc (G).
Note the apical granularity and discoid morphology (G). Statistics in Fig. S1. Scale bars, 500 nm
(A-C, F, G), 100 nm (D), 200 nm (E). R, rhoptry; N, nucleus.

Fig. 3. Plasmepsin knockdowns impair schizont protein maturation. (A) RAP1 maturation is
impaired when PM IX is knocked down, but RON4 maturation is not. PM IXapt parasites were
cultured ±aTc to 44 hpi and extracts were blotted for RAP1 (left) and RON4 (right). Arrows
mark precursor and processed RAP1 forms. (B) The second maturation step in SUB1 processing
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is defective when PM X is knocked down. PM Xapt parasites were cultured as in (A). Rabbit antiSUB1 immunoblot shows 54 kDa intermediate and 47 kDa mature SUB1 forms. (C) PM X
expression starts before SUB1 expression but SUB1 maturation coincides with the peak of
mature PM X. HA-tagged PM X parasites were cultured for varying times. Parasite extracts were
processed for immunoblot using anti-HA or anti-SUB1 antibodies. Precursor (PM X, 67 kDa;
SUB1, 54 kDa) and mature (PM X, 45 kDa; SUB1, 47 kDa) forms are marked on right. (D)
Immunoblot shows that processing of the SUB1 substrate SERA5 is impaired by PM X KD. PM
Xapt parasites were cultured for 46 hpi ±aTc and processed for immunoblot. (E, F) A catalytically
dead mutant cannot rescue PM X knockdown. PM Xapt parasites were complemented with a
second copy of the PM X gene, wild-type (WT) or mutant (D266G). Cultures were maintained
±aTc; parasitemia (E) and SUB1 processing (F) were assessed. ****p<.0001 by two-tailed t-test.
KD of PM X and expression of second copy genes were confirmed by immunoblot (Fig. S6).

67

Fig. 4. Aminohydantoin compounds act in a PM X-dependent manner and phenocopy the PM X
knockdown through a block in SUB1 processing. (A, B) Dose-response curves for compounds
incubated for 48h with PM IXapt (A) or PM Xapt (B) parasites at low (3nM) or higher (10nM)
aTc. Values are mean ±SEM. Growth of parasites at both [aTc] was similar (Fig. S8). (C, D)
CWHM-117 blocks egress at the same stage as PM X KD. Parental (NF54) parasites were
synchronized, treated with 500 nM CWHM-117 from 24 hpi and monitored for progression of
egress by live cell microscopy as in Fig. 1. (C) Successful egress and invasion was scored.
****p<.0001 (D) (1) distorted schizont, (2) merozoite cluster. Scale bar= 5 m (E)
Aminohydantoins block the final SUB1 maturation step and impair processing of downstream
substrates. Compounds were applied to PM X-3X HA cultures at 24 hpi and incubated for
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another 24 hours. Parasite extracts were analyzed for immunoblot using antibodies to SUB1,
SERA5 and HA (for PM X). D, DMSO vehicle control; 75, 0.2 uM TCMDC-134675; 79, 0.1 uM
TCMDC-136879; 117, 0.5 uM CWHM-117. (F) PM X assay. Recombinant PM X was incubated
with fluorogenic peptide for 120 min in the presence or absence of aminohydantoins. Black,
CWHM-117; green, TCMDC-136879; pink, TCMDC-134675. (G, H) PM X knockdown
combined with inhibitor treatment completely blocks egress (p<.0001) (G) and SUB1 maturation
(H). Labels and concentrations as in E. (I) Scheme of proteolytic cascade involved in egress.
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2.5 SUPPLEMENTARY MATERIALS
Materials and Methods
Figures S1-S9
References (23-29)
Reagents and antibodies
All primers were obtained from Integrated DNA Technologies. Restriction enzymes were
purchased from New England Biolabs. Anti-HA antibodies were obtained from Sigma while the
anti-Flag antibody was from ThermoFisher. Anti-SUB1 and SERA5 antibodies were kind gifts
of Dr. Michael J. Blackman (The Francis Crick Institute, London). Monoclonal antibody 2.29
(anti-RAP-1) and monoclonal antibody 12.4 (MSP1) were obtained from The European Malaria
Reagent Repository (http://www.malariaresearch.eu). The anti-HAD1 antibody was a kind gift of
Dr. Audrey Odom John (Department of Pediatrics, Washington University School of Medicine,
St. Louis, Missouri). Anti-Myc antibody (9E10) was purchased from ThermoFisher. aTc was
purchased from Cayman Chemical.

Primers
Primers for tagging PM X with 3’ Aptamers, 3XHA tag and GFP and for making PM X
complementation plasmids
LHR means left homologous region, RHR means right homologous region.
Table 2.1. Primers for tagging PM IX with 3’ Aptamers and 3XHA

Sequence

Notes

RHR F

GTACAAACCCGGAATTCGAGCTCGGCAGAG
GAAAACGAAAAATATCTCAGTTCCTTACAT

Forward primer for PCR of the
RHR of PM IX

RHR R

GGGTATTAGACCTAGGGATAACAGGGTAAT
CATTTGATGTTCCACCTTATTGCGAATTGG

Reverse primer for PCR of the
RHR of PM IX

INT P1

ATAGGAGTGGAGACATTTAAGATTGGAC

Forward primer for checking
integration of donor plasmid at 5’
end PM IX genomic locus
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INT P2

TCACAGATCTTCTTCGCTGATGAGTTTCT

Reverse primer for checking
integration of donor plasmid at 5’
end PM IX genomic locus

SgRNA
oligo 1

TAAGTATATAATATTCTATGACGTAAGTCAA
GTTGGTTTTAGAGCTAGAA

Forward primer for guide RNA
used for editing the PM IX locus

SgRNA
oligo 2

TTCTAGCTCTAAAACCAACTTGACTTACGTC
ATAgAATATTATATACTTA

Reverse primer for guide RNA
used for editing the PM IX locus

sgRNA
sequence

CTATGACGTAAGTCAAGTTG

Sequence of the guide RNA used
for editing the PM IX locus

PM2GT
PM IX
RHR F

ATACGATTTAGGTGACACTATAGAACTCGA
GCAGAGGAAAACGAAAAATATCTCAGT

Forward primer for PCR of RHR
for 3XHA PM IX tagging

PM2GT
PM IX
RHR R

ATCTACCCCTCCAAATATTAATGCAGACTTA
AGCATTTGATGTTCCACCTTATTGCGA

Reverse primer for PCR of RHR
for 3XHA PM IX tagging

PM2GT
PM IX
LHR F

ATTCGCAATAAGGTGGAACATCAAATGCTT
AAGTCTGCATTAATATTTGGAGGGGTA

Forward primer for PCR of LHR
for 3XHA PM IX tagging

PM2GT
PM IX
LHR R

GTCCGGGACGTCGTACGGGTACCTAGGCAG
GTTGTTGATTTTGTTGTGCAG

Reverse primer for PCR LHR for
3XHA PM IX tagging

PM2GT
PM
IX_P1

ATAGGAGTGGAGACATTTAAGATTGGAC

Forward primer for checking
CRISPR mediated integration of
any gene tagged using the
PM2GT plasmid

PM2GT_
P2

TATATTATATAACTCGACGCGGCCGTC

Reverse primer for checking
CRISPR mediated integration of
any gene tagged using the
PM2GT plasmid
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Table 2.2. Primers for tagging PM X with 3’ Aptamers, 3XHA and GFP.

Primer
name

Sequence

Notes

054_

GTGCGGCCGCCGGTTTACCGAGCTCTTATTG
GTTTTCAAACTTCATTGACTGTGCCGGCCGG
CCTC

Forward primer for PCR of the
LHR of PM X

ATCATCATCATCTTTATAATCCGCGATCGCG
TTTTTACTTTTTGCTCTTGCTACTCCAAC

Reverse primer for PCR of the
LHR of PM X

AGGTAGCGAATAATACGACTCACTATACTCT
TTATTGAATCCCATATTTTAATATACC

Forward primer for PCR of RHR
of PM X

GGGTATTAGACCTAGGGATAACAGGGTAAT
TATACTAGTGTATAACCTATTACATCACAT

Reverse primer for PCR of RHR
of PM X

LHR seq
1

GACACAGGTACATCTTATAATACAATG

Primer for sequencing LHR

054_

AGAGCAAAAAGTAAAAACGCGATCGCGATG
CCTAGGCCAGGTGCAGCACATTATGCAGCA

Forward primer for PCR of GFP
to tag the coding sequence of PM
X

PM X_
LHR F
054_
PM X_
LHR R
054_
PM X_
RHR F
054_
PM X_
RHR R

PM X_
LHR_
GFP F
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054_

ATTTATCATCATCATCTTTATAATCTCATTTG
TACAGTTCATCCATGCCATGTGTAATCC

Reverse primer for PCR of GFP
to tag the coding sequence of PM
X

CTCCTTATGATGGGAAGTCAACTTTA

Forward primer for checking
integration of donor plasmid at 5’
end of the PM X genomic locus

INT P2

TCACAGATCTTCTTCGCTGATGAGTTTCT

Reverse primer for checking
integration of donor plasmid at 5’
end of the PM X genomic locus

sgRNA
oligo 1

TAAGTATATAATATTATTAATAATGCATTAA
AAAAGTTTTAGAGCTAGAA

Forward primer for guide RNA
used for editing the PM X locus

sgRNA
oligo 1

TTCTAGCTCTAAAACTTTTTTAATGCATTATT
AATAATATTATATACTTA

Reverse primer for guide RNA
used for editing the PM X locus

sgRNA
sequence

ATTAATAATGCATTAAAAAA

Sequence of the guide RNA used
for editing the PM X locus

PM2GT
PM X
RHR F

TACGATTTAGGTGACACTATAGAACTCTCTT
TATTGAATCCCATATTTTAATATACCC

Forward primer for PCR of the
RHR to tag PM X with 3xHA

PM2GT
PM X
RHR R

TTCATCTAATTTTACTTCCCAGTAGGACTTA
AGCTCGTATACTAGTGTATAACCTATTAC

Reverse primer for PCR of the
RHR to tag PM X with 3xHA

PM2GT
PM X
LHR F

GTAATAGGTTATACACTAGTATACGAGCTTA
AGTCCTACTGGGAAGTAAAATTAGAT

Forward primer for PCR of the
LHR of PM X to tag PM X with
3xHA

PM X_
LHR _
GFP R
054_
PM X
INT P1
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PM2GT
PM X
LHR R

CGGGACGTCGTACGGGTACCTAGGGTTTTTA
CTTTTTGCTCTTGCTACTCCAACCATA

PM X
promAatII

GAAAAGTGCCACCTGACGTCGTTAAATAATT Forward primer for PCR of the
ATTAATTTTCCATAACCC
5’UTR+ wildtype coding
sequence of PM X for
complementation

PM X orf
rev-NheI

GAAATCAACTTTTGTTCGCTAGCGTTTTTACT Reverse primer for PCR of the
TTTTGCTCTTGCTACTCCAACC
5’UTR+ wildtype coding
sequence of PM X for
complementation

D266GM
UT

CAAACTGTATATCCAATATTTGGTACAGGAA
GTACAAATGTATGGGTAGTGACAACA
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Reverse primer for PCR of the
LHR of PM X to tag PM X with
3xHA

Primer for site directed
mutagenesis to create D266G
from the wild-type plasmid

Table 2.3 Primers for tagging SUB1 with 3XHA

Sequence

Notes

SUB1
RHR F

ATACGATTTAGGTGACACTATAGAACTTGGA
AATGGCTTTTTAAATAATATATATTTC

Forward primer for PCR of RHR
for 3XHA SUB1 tagging

SUB1
RHR R

TCATAAACAGTAGATAAGATAGGCTTAAGAC
GTGCTTGCTAATATTAACACACTACA

Reverse primer for PCR of RHR
for 3XHA SUB1 tagging

SUB1
LHR F

ATGTGTAGTGTGTTAATATTAGCAAGCACGT
CTTAAGCCTATCTTATCTACTGTTTAT

Forward primer for PCR LHR for
3XHA SUB1 tagging

SUB1
LHR R

CCGGGACGTCGTACGGGTACCTAGGATGCAA
ATATCTACTTTTTTTTTTCCACTTGTA

Reverse primer for PCR of LHR
for 3XHA SUB1 tagging

PM2GT
_SUB1
P1

GTAGTCATCCTAAATCGTCAACACC

Forward primer for checking
CRISPR mediated editing of the
SUB1 locus

PM2GT
_P2

TATATTATATAACTCGACGCGGCCGTC

Reverse primer for checking
CRISPR mediated integration of
any gene tagged using the
PM2GT plasmid

sgRNA
oligo 1

TAAGTATATAATATTGCATTAACTAGTACATC Forward primer for guide RNA
AAAGTTTTAGAGCTAGAA
used for editing the SUB1 locus

sgRNA
oligo 2

TTCTAGCTCTAAAACTTTGATGTACTAGTTAA
TGCAATATTATATACTTA

Reverse primer for guide RNA
used for editing the SUB1 locus

sgRNA
sequenc
e

GCATTAACTAGTACATCAAA

Sequence of the guide RNA used
for editing the SUB1 locus
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Table 2.4 Primers for tagging RON4 with 3XHA

Sequence

Notes

RON4
RHR F

cgatttaggtgacactatagaactTCTGTTTATACAAGTAT
AAGCCCAAACAAACAT

Forward primer for PCR of RHR
for 3XHA RON4 tagging

RON4
RHR R

CTGAACATTTATATAACATATCTGTTAGGCG
ATCGCATAAGAATGTATAGGAATATGTTC

Reverse primer for PCR of RHR
for 3XHA RON4 tagging

RON4
LHR F

GAACATATTCCTATACATTCTTATGCGATCGC
CTAACAGATATGTTATATAAATGTTCAG

Forward primer for PCR of RHR
for 3XHA RON4 tagging

RON4
LHR R

GCGTAGTCCGGGACGTCGTACGGGTATAAAT
CATCAAAAATCATCTTTTCAGCATCGTCT

Reverse primer for PCR of LHR
for 3XHA RON4 tagging

PM2GT
_RON4
P1

AGGCAACAGCTCAAAGAATTAATTCTTAC

Forward primer for checking
CRISPR mediated editing of the
RON4 locus

PM2GT
_P2

TATATTATATAACTCGACGCGGCCGTC

Reverse primer for checking
CRISPR mediated integration of
any gene tagged using the
PM2GT plasmid

sgRNA
oligo 1

TATTAAGTATATAATATTTCTGTTTATACAAG
TATAAGGTTTTAGAGCTAGAAATAG

Forward primer for guide RNA
used for editing the RON4 locus

sgRNA
oligo 2

CTATTTCTAGCTCTAAAACCTTATACTTGTAT
AAACAGAAATATTATATACTTAATA

Reverse primer for guide RNA
used for editing the RON4 locus

sgRNA
sequenc
e

TCTGTTTATACAAGTATAAG

Sequence of the guide RNA used
for editing the RON4 locus
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Plasmid Cloning
All plasmids were verified by sequencing.
Plasmid cloning for aptamer regulation of PM IX
To install aptamers on the 3’ end of PM IX, the pMG57 plasmid (12) was modified as follows.
Briefly, the TetR-DOZI2ABSD2ARLUC cassette was moved from pMG57 into the NotI site of
the linear pJAZZÒ plasmid (Lucigen). A multiple cloning site was also added to the plasmid
allowing the next cloning steps. The linear vector was then modified to install the 10X aptamer
and HSP86 3’UTR. Upstream of the 10X aptamers, an AsiSI site was inserted to allow cloning
of LHRs. Downstream of the TetR-DOZI-BSD-RLUC cassette, an I-SceI site was inserted to
clone RHRs (see Fig. S1 for illustration of this modified vector).
The RHR (RHR), ~450bp of PM IX coding sequence immediately downstream of the stop codon
of PM IX, was PCR amplified and cloned into the I-SceI site of the parent plasmid described
previously. The 3’ region of the coding sequence of PM IX has short exons separated by introns.
To allow efficient cloning and sequencing, the last 3 introns were removed and the exons were
combined to make a contiguous coding sequence. These exons were re-codonized to Toxoplasma
gondii codon bias. The exon before the most upstream intron was used as the LHR (LHR).
Together, the LHR and re-codonized portion were ordered as a gene block from IDT. This gene
block was cloned, using Gibson AssemblyÒ, into AsiSI sites of the RHR containing plasmid,
creating an in-frame fusion with a 2xFLAG tag at the 3’ end of the LHR. Below is the sequence
of the LHR (bold) and the re-codonized region (introns removed- italics). Gibson cloning
overhangs are in lowercase. FLAG tags are underlined.
ggttttcaaacttcattgactgtgccggccggccTCTGCATTAATATTTGGAGGGGTAGATAAAAATTT
TTTTGAAGGAGATATATATATGTTTCCTGTTGTTAAGGAATATTATTGGGAAAT
CCATTTTGATGGTTTATATATTGATCATCAGAAATTTTGTTGTGGTGTTAATTCT
ATTGTATATGATTTAAAAAAAAAAGATCAAGAAAATAATAAATTATTTTTTACGA
GAAAATATTTTAGAAAAAATAAATTCAAAACTCATTTAAGAAAATATCTTCTTAA
AAAAATAAAACATCAAAAAAAACAAAAACATTCTAATCATAAAAAAAAAAAATT
AAACAAGAAAAAAAATTACTTAATTTTTGATTCTGGAACATCTTTTAATAGTGTC
CCAAAGGATGAAATCGAATATTTCTTTCGTGTCGTTCCTTCAAAGAAGTGCGACG
ACTCGAATATTGACCAGGTTGTCTCGAGTTATCCCAACCTCACTTACGTGATCAATAAGATG
CCGTTTACATTGACACCTAGCCAATACCTGGTTAGGAAAAATGACATGTGCAAACCTGCTT
TCATGGAGATTGAAGTTTCCAGTGAGTACGGGCACGCGTACATCTTGGGAAACGCCACCT
TCATGAGGTATTACTACACTGTGTACCGTCGAGGAAACAATAATAACTCTTCTTACGTTGGA
ATCGCTAAAGCAGTCCACACCGAGGAGAATGAAAAATATCTCTCGTCCCTGCACAACAAAA
TCAACAACCTGGACTACAAGGACGACGATGACAAGgcgatcgcggattataaagatgatgatgataaatga
cgtacgg
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Plasmid cloning for aptamer regulation of PM X
The RHR of PM X (400bp of 3’UTR) was cloned into the I-SceI site of the parent plasmid
described previously. The resulting plasmid was digested with AsiSI and the LHR PCR product
(432bp upstream of the stop codon) was cloned into this site. The PM X gene was tagged with a
1X FLAG tag.
PM IX plasmid for creating the PM IX and X double aptamer regulation strain
To create the PM IX and X dual aptamer regulated line (Fig. S2), the PM IX aptamer plasmid
described previously was modified by replacing the TetR-DOZI-BSD cassette with a yDHODH
resistance gene cassette (Fig. S2) using the BmtI and AhdI restriction sites. The yDHODH
cassette was PCR amplified from the pyEOE plasmid (23).
Cloning of plasmids for tagging PM IX, PM X, SUB1 and RON4 with a triple Hemagglutinin
(3X HA) tag
For tagging genes with a 3XHA, the PM2GT plasmid (24) was used. This plasmid was modified
to replace the GFP gene with a 3XHA tag
(TACCCGTACGACGTCCCGGACTACGCTGGCTATCCCTATGATGTGCCCGATTATGCG
TATCCTTACGATGTTCCAGATTATGCC) using the QuickChange Lightning Multi-Site
mutagenesis kit (Agilent). The modified PMGT_3XHA plasmid was digested with AvrII and
XhoI. The RHR and LHR pieces of the genes of interest were PCR amplified from NF54attB
genomic DNA and attached to each other via Gibson assembly. The RHR+LHR combination
was then PCR amplified using the RHR forward primer and LHR reverse primer and this PCR
product was cloned into the linearized PM2GT plasmid. An AflII site was inserted between the
RHR and LHR pieces. After cloning the piece into PM2GT_3XHA plasmid, the plasmid was
linearized with AflII for transfection. Because the LHR of RON4 contained an AflII site, an
AsiSI site was inserted between the RHR and LHR for linearization pre-transfection.

Cloning of sgRNAs for CRISPR/Cas9 modification of gene loci
Complementary sense and antisense oligos encoding the sgRNAs for CRISPR/Cas9 editing were
annealed and cloned into the U6 promoter-based sgRNA expression cassette of the pyAIO
plasmid as previously described (25).
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Cloning of complementation plasmids
To complement the PM X knockdown, we first modified the plasmid pyEOE (24) to allow for
Bxb1 integrase-mediate genomic integration (27) by inserting a 2xattP sequence into the vector
backbone sequence using the QuickChange Lightning Multi-Site mutagenesis kit (Agilent) with
the primer 5’GGTCGACTCTAGAGGATCCCCGGGTACCGAGCTCGAATTCTGGTTTGTCTGGTCAAC
CACCGCGGTCTCAGTGGTGTACGGTACAAACCCGAATTCTGGTTTGTCTGGTCAACC
ACCGCGGTCTCAGTGGTGTACGGTACAAACCCGGAATTCTAGATTTAATAAATATGT
TCTTATATATAATG -3’. A 3xMYC epitope tag was then inserted between XhoI and EagI
using the QuickChange Lightning Multi-Site mutagenesis kit and the primer 5’CGAATAAACACGATTTTTTCTCGAGGCTAGCGAACAAAAGTTGATTTCTGAAGAAGA
TTTGAACGGTGAACAAAAGCTAATCTCCGAGGAAGACTTGAACGGTGCTAGGGCCG
AGGAGCAGAAGCTGATCTCCGAGGAGGACCTGTGACGGCCGCGTCGAGTTAT-3’. An
NheI site was included at the 5’ end of the 3xMYC sequence. This resulted in the vector pyEOE2xattP-3xMYC. The PM X genomic locus including ~2kb upstream of the start codon (promoter
region) and the entire coding sequence was PCR amplified from NF54 genomic DNA (~3.7kb
total). This PCR product was cloned into the pyEOE-2xattP-3xMYC plasmid between the XhoI
and NheI sites, resulting in the plasmid pyEOE-2xattP-PM X-3xMYC-WT. This plasmid was
then mutagenized (QuikChange®, Agilent) to create the D266G mutant using primers listed
previously.

Cloning PM X and SUB1 for expression in mammalian cells
To express PM X in mammalian cells, an S. cerevisiae recodonized PM X gene (a truncated
version comprising ~40kDa of the catalytic domain) was cloned into the AgeI and KpnI sites of
the vector pHLSEC (Addgene) by Gibson assembly. The recodonized sequence is shown here.

ATGTCAGATAATTCCAGTATCGAGAAAAACTTTATCGCTCTTGAAAATAAGAACGCT
ACCGTGGAGCAGACCAAAGAGAATATCTTCCTGGTGCCATTGAAGCATCTAAGGGA
CTCACAATTTGTCGGAGAATTGTTGGTAGGCACACCCCCACAGACTGTGTATCCAAT
CTTCGACACCGGCTCTACTAACGTTTGGGTAGTCACTACTGCCTGTGAGGAGGAAAG
TTGTAAAAAAGTGCGTAGGTACGATCCCAACAAATCCAAAACATTCAGGAGGTCCT
TTATTGAAAAGAATTTACATATTGTATTTGGGTCTGGATCTATAAGTGGTTCCGTCGG
TACCGATACCTTTATGTTGGGGAAACATCTGGTCAGAAACCAAACATTTGGCTTAGT
TGAATCCGAGAGCAATAATAACAAGAATGGTGGAGATAATATTTTCGACTATATATC
TTTTGAAGGAATTGTTGGCCTGGGCTTTCCAGGCATGTTAAGTGCAGGTAACATTCC
TTTTTTCGATAACCTTTTAAAGCAAAATCCAAACGTCGATCCCCAATTTTCTTTCTAT
ATATCTCCTTACGATGGCAAAAGCACTCTAATCATCGGTGGCATCTCTAAATCTTTCT
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ACGAGGGAGATATCTATATGCTTCCTGTCCTGAAGGAATCCTATTGGGAAGTTAAGC
TGGACGAACTATACATCGGAAAAGAGCGTATATGCTGCGATGAGGAAAGTTATGTG
ATATTTGACACGGGGACATCATACAATACAATGCCTTCCTCTCAGATGAAGACATTT
CTGAATCTAATTCACAGCACGGCGTGCACCGAGCAAAATTATAAAGACATATTGAA
GTCCTACCCAATTATCAAATACGTCTTTGGAGAACTGATCATCGAATTACACCCGGA
AGAATATATGATATTAAATGATGACGTATGCATGCCTGCTTACATGCAGATAGACGT
CCCCTCTGAGAGGAACCATGCCTACCTGCTTGGTTCTCTGAGCTTTATGCGTAACTTT
TTCACGGTCTTTGTCAGGGGGACTGAAAGCAGGCCAAGCATGGTCGGTGTCGCACGT
GCTAAAAGCAAGAACTATCCTTACGATGTCCCGGACTACGCTTACCCGTATGATGTG
CCTGACTACGCATATCCGTACGACGTTCCTGACTACGCG

To express SUB1 p82 in mammalian cells, a mammalian re-codonized SUB1 gene (full-length
minus the signal peptide) was cloned into the AgeI and KpnI sites of pHLSEC. The recodonized
sequence is shown below.
AAGGAAGTGAGGTCCGAGGAAAACGGTAAAATCCAGGACGACGCGAAAAAAATTG
TGTCTGAATTGCGCTTCCTTGAAAAGGTTGAGGATGTTATTGAAAAGTCTAACATTG
GCGGGAACGAGGTAGATGCGGACGAGAACTCCTTTAACCCTGATACGGAAGTCCCC
ATCGAAGAGATTGAGGAGATAAAAATGCGCGAACTGAAAGATGTGAAAGAAGAAA
AGAATAAAAATGACAATCATAACAATAATAACAACAATATAAGTTCCAGCAGCTCA
AGCTCCTCAAACACGTTTGGGGAAGAGAAGGAGGAGGTTTCAAAGAAGAAAAAGA
AGCTGCGCCTTATAGTTAGCGAAAATCACGCAACCACACCAAGTTTTTTTCAGGAAT
CTCTGCTGGAACCGGACGTATTGTCATTTCTCGAGTCTAAGGGCAATCTTAGCAACC
TCAAGAATATCAATTCTATGATCATAGAGCTCAAAGAGGACACGACCGATGATGAG
CTTATTAGCTATATCAAAATTCTTGAGGAAAAGGGTGCCCTTATTGAATCCGATAAA
CTCGTCTCAGCCGATAACATTGATATCAGCGGGATAAAGGATGCAATCCGGAGAGG
AGAAGAGAACATTGATGTCAATGATTACAAATCTATGTTGGAAGTAGAAAACGACG
CAGAGGATTATGACAAGATGTTTGGTATGTTTAATGAAAGTCATGCCGCGACTAGTA
AACGAAAAAGGCATTCCACCAATGAAAGAGGATACGACACATTCAGTAGTCCATCA
TACAAGACTTACTCCAAAAGTGATTACTTGTACGACGATGACAATAACAACAATAAT
TATTATTATTCTCACTCATCTAACGGACACAACAGCAGTTCCAGAAACTCATCCTCTT
CCCGGAGTCGGCCGGGCAAGTATCATTTCAACGACGAGTTCCGAAATCTGCAGTGG
GGATTGGATCTCTCCCGGCTTGACGAAACCCAAGAACTGATAAATGAGCACCAGGT
GATGAGCACTAGAATCTGCGTGATAGACAGCGGTATTGACTACAATCATCCAGATCT
GAAGGATAATATAGAATTGAATCTCAAGGAGCTCCATGGGCGCAAAGGCTTTGATG
ATGATAACAACGGGATTGTCGATGACATTTATGGAGCCAACTTTGTGAATAACTCCG
GAAATCCTATGGATGATAATTACCACGGAACGCACGTATCCGGCATCATAAGCGCC
ATCGGAAACAACAACATCGGGGTAGTCGGAGTTGACGTGAATAGTAAGCTGATCAT
TTGCAAAGCCTTGGACGAGCATAAGCTTGGCCGACTTGGCGACATGTTCAAATGCTT
GGACTATTGCATATCCCGCAATGCGCATATGATCAATGGCTCATTCTCTTTTGACGA
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ATACTCAGGGATATTTAATTCCTCCGTTGAGTATTTGCAAAGAAAGGGTATTCTCTTT
TTTGTATCCGCATCAAATTGTAGCCATCCCAAATCTAGTACGCCCGATATCCGCAAG
TGCGATCTGTCCATAAATGCCAAATACCCGCCGATATTGAGCACTGTCTATGATAAC
GTAATATCCGTAGCTAACCTGAAAAAAAATGATAACAACAACCACTACAGCTTGTCT
ATTAATTCATTCTACAGCAACAAGTACTGCCAGCTCGCTGCCCCGGGTACAAATATA
TATAGCACGGCGCCCCACAATAGTTACCGGAAGCTTAATGGGACATCCATGGCCGC
ACCGCATGTCGCGGCCATCGCATCCCTCATATTCTCTATCAACCCCGACCTCTCTTAC
AAAAAGGTTATCCAAATACTTAAAGATAGTATAGTATATTTGCCAAGCCTCAAGAAC
ATGGTTGCATGGGCCGGTTATGCCGACATTAACAAGGCCGTAAACTTGGCAATCAA
GTCAAAGAAGACTTATATTAATAGCAATATATCTAACAAATGGAAAAAGAAGAGTA
GGTACCTCCAT
Parasite culture, transfection and synchronization
NF54attB parasites (28) and resultant transgenic strains were cultured in human red blood cells
as previously described (26). For creating the aptamer-regulated PM IX and X lines, 50µg of
aptamer plasmid was co-transfected with 50µg of the sgRNA and Cas9-carrying plasmid.
Immediately following transfection, 1µM aTc was introduced into the cultures and maintained
from that time forward. Parasites were selected with 2.5ug/ml BSD beginning 24 hours after
transfection.
For complementation of PM X, plasmids carrying WT or mutant PM X coding sequences were
independently co-transfected with the Bxb1 integrase (27) plasmid into the PM Xapt parasites.
Parasites were selected with 12.5µg/ml DSM-1 together with 2.5µg/ml BSD and 1µM aTc. The
integration of these plasmids into PM Xapt strain was confirmed by PCR using the following
primers: 5’-TTTTTGTAGACCCCATTGTGAGTACATAAAT-3’ and 5’CATTTGAATTATTGCTCAACGCT-3’

Highly synchronous ring-stage parasites were obtained as follows. High parasitemia schizonts
cultures were passed through MACS LD magnet columns (Miltenyi Biotec) and schizonts were
collected. These were then added to fresh uninfected RBCs resuspended in warm culture media.
The cultures were shaken at 80 RPM for 2 hours and the resulting parasites were synchronized
using 5% sorbitol and returned into culture.
For analysis of PM Xapt parasite analysis, the population of parasites generated was cloned. The
five clones picked behaved the same in growth assays and two clones were used for the rest of
our experiments.
Western blotting analyses
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For PM IX and X knockdown Western blots (Fig. 1A), highly synchronous ring-stage parasites
were washed three times (10 minute wait each time), supplemented with fresh blood and split
into +/- aTc plates. After 24 hours the cultures were treated with 500 nM compound 1 (29) to
prevent egress, allowing the accumulation of parasites as late, segmented schizonts. The
schizonts were collected using MACS columns, lysed in RIPA buffer supplemented with
protease inhibitor cocktail, sonicated for 15 seconds and centrifuged 3x at 13300g for 10 minutes
each time. Supernatants were transferred to new tubes after each spin to get rid of hemozoin.
Supernatants were mixed with 5X sample buffer and boiled at 99°C for 5 minutes.
For MSP1 Western blotting (Fig. 3D), highly synchronous ring-stage parasites were washed
three times (10 minute wait each time), supplemented with fresh blood and split into +/- aTc
plates. After 24 hours the cultures were treated with 500 nM compound 1 (29) to prevent egress,
allowing the accumulation of parasites as late, segmented schizonts. After 50 hours, the schizonts
were washed 3x to get rid of compound 1. One hour later the schizonts were collected using
MACS columns and processed similarly to what was done for Fig. 1A.
For all other Western blots, highly synchronous (2-hour window) parasites were created. These
were washed to eliminate aTc as described before and split into +/- aTc conditions. The parasites
were carefully monitored until new rings started emerging, suggesting that parasites had reached
the end of their cycle. The schizonts in the cultures were then purified by MACS columns and
processed for Western blotting as described previously.
For Western blots showing effects of PM X inhibitor treatment (Fig. 4E, F), compounds were
added to trophozoites and schizonts were harvested and processed for Western blotting.
Total protein was separated by SDS-PAGE. The resolved proteins were transferred onto a
nitrocellulose membrane (Bio-Rad). The membrane was then blocked with blocking buffer
(Licor) for 30 minutes and probed with the appropriate primary antibody in Licor blocking buffer
and then the appropriate secondary antibody. Blots were visualized on an Odyssey imaging
system (Licor). Quantification of band intensity was performed using Image Studio (Licor). All
primary antibodies for Western blotting were used at 1:1000 dilutions in Licor blocking buffer.
The secondary antibodies were used at 1:5000 dilution in PBS+0.05% TweenÒ 20 (Sigma).
Brefeldin A Experiment
Relatively synchronous troph and schizonts stage NF54attB_PM X_3XHA parasites were
harvested by MACs purification. These were split into two cultures, one treated with DMSO
vehicle only and the other supplemented with 0.5ug/ml brefeldin A (BFA) (24).
This is 1/10 of the amount of BFA normally used. 4 hours after treatment, parasites were
collected and prepared for Western blotting for both PM X_3xHA and SUB1.
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Electron Microscopy
Infected RBCs were fixed in 4% paraformaldehyde (Polysciences Inc., Warrington, PA) in
100mM PIPES/0.5mM MgCl2, pH 7.2 for 1 hr at 4°C. Samples were then embedded in 10%
gelatin and infiltrated overnight with 2.3M sucrose/20% polyvinyl pyrrolidone in PIPES/MgCl2
at 4°C. Samples were trimmed, frozen in liquid nitrogen, and sectioned with a Leica Ultracut
UCT cryo-ultramicrotome (Leica Microsystems Inc., Bannockburn, IL). 50 nm sections were
blocked with 5% FBS/5% NGS for 30 min and subsequently incubated with appropriate primary
antibodies for 1 hr, followed by appropriate secondary antibodies conjugated to 12nm or 18 nm
colloidal gold (1:30) for 1 hr. Sections were washed in PIPES buffer followed by a water rinse,
and stained with 0.3% uranyl acetate/2% methyl cellulose and viewed on a JEOL 1200EX
transmission electron microscope (JEOL USA, Peabody, MA) equipped with an AMT 8
megapixel digital camera (Advanced Microscopy Techniques, Woburn, MA). All labeling
experiments were conducted in parallel with controls omitting the primary antibody which was
consistently negative at the concentration of colloidal gold conjugated secondary antibodies used
in these studies.
For EM without immunostaining, cells were fixed in 2% paraformaldehyde/2.5% glutaraldehyde
(Polysciences Inc., Warrington, PA) in 100 mM sodium cacodylate buffer, pH 7.2 for 1 hr at
room temperature. Samples were washed in sodium cacodylate buffer and postfixed in 1%
osmium tetroxide (Polysciences Inc.) for 1 hr. Samples were then rinsed extensively in dH20
prior to en bloc staining with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for 1
hr. Following several rinses in dH20, samples were dehydrated in a graded series of ethanol and
embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 95 nm were cut with a Leica Ultracut
UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained with uranyl acetate
and lead citrate, and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA
Inc., Peabody, MA) equipped with an AMT 8 megapixel digital camera and AMT Image Capture
Engine V602 software (Advanced Microscopy Techniques, Woburn, MA).
Flow cytometry
Flow cytometry for determination of parasitemia and progression of the cell cycle was performed
by incubating 15 µl of parasites cultures in 165 µl of 0.8 µg ml−1 acridine orange in PBS for 1
minute. Stained parasites were analyzed on a BD FACS Canto flow cytometer gating on DNA
and RNA-bound dye signal using FITC and PerCP-Cy5.5 filters, respectively. 50,000 events
were recorded for each sample.
Inhibitor Sensitivity Assays
To determine if the inhibitors acted in a PM IX or X dependent fashion, we first performed an
aTc titration on our PM IXapt and Xapt strains to determine a concentration at which there was a
substantial protein knockdown but normal parasite proliferation. At 3nM aTc, parasites
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consistently expanded similarly to the 10nM aTc condition (Fig. S6) for both strains. To
determine shifts in the EC50 of these compounds upon KD of PM IX and X, we performed drug
assays comparing EC50 at 10nM and 3nM aTc. Ring-stage parasites were washed 3X (10 min
wait each time) in RPMI medium to remove aTc. The cultures for each were then expanded to
larger volumes and split into 10nM and 3nM aTc conditions. These were plated in 24-well plates
with triplicates for each inhibitor concentration. These experiments were repeated at least 3 times
to evaluate shifts in dose response. The inhibitors were dissolved in 100% DMSO. The final
DMSO concentration in these assays was 0.1%.

Live cell imaging
We performed live-cell recording as described (13) for assessment of parasite egress with some
modifications to evaluate parasite invasion as well. Briefly, erythrocytes infected with late-stage
parasites were isolated and mixed with uninfected erythrocytes to 1% hematocrit and placed in
environmental chambers for two hours. Three hundred late stage parasites were monitored for
egress in each experiment. Parasites were scored as egressed or not. Additionally, for parasites
that did egress, the number of new invasions per each egress site was scored. Invasion counts
were performed for thirty sites of egress in each experiment.
PM X expression and enzyme assays
To produce recombinant PM X (catalytic domain), pHLSEC_PM X was expressed in Expi293
cells (Thermo Fisher). Briefly, cells were seeded at 5 x 106 cells/ml a day prior to transfection.
200 µg of pHLSEC-PM X was diluted in Opti-MEM (Thermo Fisher) and incubated with
HYPE-5 transfection reagent (Oz Biosciences). The DNA and transfection reagent complex was
then added dropwise to cells. Transfected cells were supplemented daily with Expi293
expression medium (Thermo Fisher) and 2% (w/v) Hyclone Cell Boost Supplement (GE). The
growth medium was collected after 4 days and 0.22µm filtered (Corning). The supernatant was
concentrated using 10 kDa MWCO concentrators (AmiconÒ Ultra-15). Reactions (200µl)
contained 50mM NaOAc/20mM NaCl pH 5.0 with 5µl of concentrated supernatant (enzyme),
0.5µM of the fluorogenic aspartic protease substrate M-2455 (Bachem) and various dilutions of
inhibitor. Fluorescence was measured every two minutes over a two-hour time course using a
CytationÔ 3 (BioTek). Protein prepared from a no PM X control plasmid was used as control.
Pepstatin was used as an aspartic protease inhibitor control. DMSO solvent was kept at 0.1% for
all samples.
SUB1 expression and cleavage assays- Full-length SUB1 was expressed in Expi293 cells as for
PM X above. SUB1 was incubated with PM X for 4 hrs at 37 °C in assay buffer described in the
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previous section. SUB1
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Fig. S1. Editing of PM IX and X loci to generate aptamer-regulated strains. (A) Schematic for
modifying PM IX/X loci with TetR-aptamer system. FLAG tag and aptamers (lollipop) were
integrated by homologous recombination to repair CRISPR/Cas9-induced double-strand breaks.
Upon aTc withdrawal, translation is blocked, leading to protein knockdown (KD). TetR_BSD=
TetR/ blasticidin-S deaminase cassette. (B) Schematic of the native loci and editing plasmids.
5'UTR= 5' untranslated region; 3'UTR = 3' untranslated region; LHR= LHR; FLAG= flag
epitope tag; HSP86 3'UTR= 3' untranslated region of the HSP86 gene used to drive expression of
modified plasmepsin gene; TetR-DOZI= Tet repressor protein fused to DOZI effector; 2A= T2A
viral skip peptide; BSD= blasticidin resistance marker; RLUC= renilla luciferase; RHR=
RHR; p1= PCR primer on genomic locus upstream of LHR; p2= PCR primer on donor plasmid
between FLAG and the aptamers (this is a common primer for both PM IX and X). (C) PCR
diagnostic test for integration in PM IXapt strain using p1 of PM IX and p2. Expected size of
PCR product is 1083bp. 1= PM IXapt strain; 2= parental strain; M= DNA ladder (D) PCR
diagnostic test for integration in PM Xapt strain using PM X p1 and p2. Expected size of PCR
product is 593bp. 1= parental strain; 2= PM Xapt. (E, F) Parasites grown in –aTc culture for 3 or
4 cycles become insensitive to aTc withdrawal after they recover. (E) Representative growth
curves for PM Xapt parasites grown in -aTc over 3 or 4 cycles. Synchronous ring stage parasites
were grown -aTc and the parasitemia was determined by flow cytometry. After 3 (top) or 4
(bottom) cycles aTc was added back to these cultures and the parasitemia was monitored for 3
more cycles. After the third cycle, recovered parasites were washed 3 times to get rid of aTc and
then grown +/-aTc for one more cycle (Inserts in E). Parasitemia was determined by flow
cytometry. (F) PCR diagnostic test using p1 and p3 to assess the editing and aptamer status of
parasites recovered after 3 or 4 cycles of aTc withdrawal. Parasites from day 12 of (E) were
collected. Expected size of PCR product is 1.5kb. 1= parental strain; 2= PM Xapt; 3=PM Xapt
recovered after being grown –aTc for 3 cycles; PM Xapt recovered after being grown –aTc for 4
cycles. An accumulation of truncated aptamer-array containing parasites was seen over time in
culture. (G) PM IXapt rhoptry morphology statistics. Rhoptries from 30 cryoEM sections
including the ones in Fig.2F-H were scored as bulbar (elongated) or round. Of round crosssections, 0/26 displayed discoid morphology in the +aTc culture and 25/47 in the –aTc culture.
Of bulbar cross-sections, 2/26 displayed granular morphology in the +aTc culture and 16/23 in
the –aTc culture. ****p<.0001 for each (Fisher’s exact test).
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Fig. S2. Editing the PM Xapt strain with a PM IX donor vector to create the PM IXapt/Xapt double
knockdown strain. (A) Schematic of the PM IX plasmid modified from the one in Fig. S1 by
replacement of the TetR_BSD_RLUC region with yDHODH resistance marker. All labels are
the same as in Fig. S1. (B) PCR diagnostic test of PM IXapt/Xapt to confirm editing. 1, 4= parental
strain; 2, 5= PM Xapt strain; 3, 6= PM IXapt/Xapt strain. Expected PCR product sizes are 593 bp
and 1083 bp for PM X and PM IX editing respectively. (C) Representative growth curve for PM
IXapt/Xapt parasites over two cycles. Synchronous ring stage parasites were grown +/-aTc and the
parasitemia was determined by flow cytometry. The +aTc culture was split back to ~2%
parasitemia and supplemented with fresh RBCs on day 2 (arrow) to avoid overexpansion (D)
Parasite stage upon maturation ± aTc. Parasites from (C) were monitored at 44 and 52 hpi.
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Schizonts and new rings were counted by flow cytometry. (E) Merozoite cluster typical of
culture –aTc. (F,G) PM IXapt/Xapt grown in –aTc media for 3 cycles (F) or 4 cycles (G) do not
reappear when supplemented with aTc again.
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Fig. S3. Editing of PM IX, PM X, RON4 and SUB1 loci to generate triple HA (3X HA) and GFP
tagged genes. (A) Schematic of the native loci and editing plasmids. 5'UTR= 5' untranslated
region; 3'UTR = 3' untranslated region; LHR= LHR; HA= hemagglutinin epitope tag; GFP=
green fluorescent protein; HSP86 3'UTR= 3' untranslated region of the HSP86 gene used to drive
expression of the modified plasmepsin gene; yDHODH= yeast dihydroorotate dehydrogenase
resistance gene; p1= PCR primer on genomic locus upstream of LHR; p2= PCR primer on donor
plasmid downstream of the HA or GFP tags. (B) PCR diagnostic test of PM IX_3XHA strain
using p1 of PM IX and p2. Expected size of PCR product is 1083bp. (C) PCR diagnostic test of
PM X_3XHA strain using PM X p1 and p2. Expected size of PCR product is 593bp. 1,2 = PM
X_3XHA transfections 1 and 2; 3= parental strain (D) Immunoblotting with anti-HA antibody
showing correct tagging of PM IX protein. (Correct tagging of PM X is shown in Fig. 3B). (E)
PCR diagnostic test of PM IX:RON4_3XHA strain using RON4 p1 and p2. Expected size of
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PCR product is ~730bp. 1= PM IX parental strain. 2=PM IX:RON4_3XHA strain. (F) PCR
diagnostic test of PM IX:SUB1_3XHA, PM X_SUB1_3XHA and NF54_SUB1_3XHA strains
using SUB1 p1 and p2. Expected size of PCR product is ~550bp. 1,2= PM X:SUB1_3XHA; 3=
PM IX_SUB1_3XHA, 4= NF54_SUB1_3XHA; NF54 parental strain.
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Fig. S4. Knockdown of PM X but not PM IX impairs SUB1 processing. PM IXapt and PM Xapt
parasites, in which the SUB1 gene was tagged with a 3XHA, were cultured for 46 hpi ±aTc and
processed for immunoblot using anti-HA antibodies (green). HAD1 is the loading control (red).
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Fig. S5. PM X maturation is blocked by brefeldin A (BFA). (A, B) Troph and schizont stage PM
X_3XHA parasites were cultured for 4 hours in 0.5ug/ml of BFA and processed for immunoblot
using anti-HA antibodies for PM X (A) or anti-SUB1 antibodies (B).
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Figure S6. PM X knockdown results in accumulation of MSP1 precursor. Highly synchronous
PM Xapt parasites were cultured to 44 hpi ±aTc and magnet-purified. Compound 1 was added at
1 uM for 4 hrs, washed out and parasites were left for 1 more hour. Extracts were prepared for
Western blot using whole schizont-infected erythrocytes. Immunoblot was performed with mAb
anti-MSP1 12.4 and 9.8, which recognize full-length MSP1 at 193 kDa. MSP1 was quantified by
densitometry, normalized to HAD1 loading control. MSP1 accumulation was 1.9±0.3 fold higher
in the –aTc condition. Results are similar to those of Blackman and colleagues for inhibition of
SUB1 (16).
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Fig. S7. Complementation of the PM Xapt line with WT and mutant second copies. (A) Anti-flag
immunoblot showing KD of PM X expression upon aTc withdrawal from WT and D266G
complementation strains. Ring-stage parasites were cultured +/- aTc and mature schizonts were
prepared for blotting using anti-Flag antibodies (B) Expression of second copy WT and D266G
proteins. Lysate from (A) was probed with anti-Myc antibodies. Pro and mature forms are
marked on right. (C) PCR confirming integration of plasmid constructs encoding WT and
D266G complementation copies of PM X. PCR was done using one primer on the chromosome
near the Cg6 locus and a primer on our integrated plasmid. Expected PCR product size = ~10kb
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Fig. S8. aTc titration growth curves for PM IXapt and PM Xapt. Representative growth curves for
PM IXapt (A) and PM Xapt (B) parasites over one cycle used for drug assays. Synchronous ring
stage parasites were grown at the indicated aTc concentrations and the parasitemia was
determined by flow cytometry. Western blots showing KD of protein expression are shown in
Fig. 1B. (C) There is no shift in EC50 between 1µM (black) and 10nM aTc (orange) on the PM
Xapt line. (In A; compared to 1uM aTc, t-test, p<0.0001 for 0nM aTc. In B; compared to 1uM
aTc, t-test, p<0.0001 for 0nM aTc)
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Fig. S9. PM X in vitro assays. (A) Progress curves for reaction of PM X with fluorogenic
substrate (Blue curve is PM X, black curve is no PM X media control). (B) Cleavage of SUB1 by
PM X in vitro. Full-length recombinant SUB1 was expressed and was isolated as the p54 form
that is generated by autoprocessing during biosynthesis (18). SUB1 was incubated with
recombinant PM X at pH 5.0 and cleavage was assessed by Western blot. Control incubations
with CWHM-117 (10 uM) gave no cleavage (not shown).
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CHAPTER 3

This is a manuscript we have in preparation.
Contributions: S.M and M.P purified the recombinant PM X enzyme and suggested corrections
to the manuscript. I performed all other experiments presented here and wrote the first draft of
the manuscript. D.E.G supervised all the work and edited the manuscript.
Running title: Maturation of SUB1 by PM X in malaria parasites
Armiyaw S. Nasamu, Sumit Mukherjee, May Paing and Daniel E. Goldberg

3.1 ABSTRACT
Egress in Plasmodium falciparum is a complex process involving a proteolytic cascade. The
aspartic protease plasmepsin X (PM X) regulates egress through maturation of the serine
protease subtilisin-like protease 1 (SUB1). In the absence of PM X, SUB1 accumulates as an
intermediate 54kDa form (p54) which remains tightly bound to the inhibitory SUB1 prodomain
(PD). The mechanism by which PM X mediates the conversion of the p54 form to the active 47
KDa form (p47) is unknown. Here, we show that when PM X is depleted by knockdown in
parasites, the PD of SUB1 accumulates tightly bound to p54. Using recombinant PM X and PD,
we show that PM X cleaves the PD and this cleavage is blocked by the PM X inhibitor CHW117. We have mapped the PD cleavage and show that there are two redundant sites. rp54 (from
full length SUB1) is not cleaved by PM X under our conditions. Altogether, these results suggest
that PM X mediates SUB1 maturation by relieving the immature p54 of PD, allowing possible
auto cleavage of p54 to p47. This unusual activation mechanism may ensure that SUB1 remains
dormant until needed to affect the egress program. We will validate all these cleavage sites in
parasites
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3.2 INTRODUCTION
Malaria remains a huge global health burden claiming the lives of close to half a million people
annually, mostly children under the age of five in sub-Saharan Africa (1). The parasites
Plasmodium falciparum is the deadliest of the Plasmodium species causing malaria in humans.
During the intraerythrocytic stage of parasite development, each parasite replicates by
schizogeny to form 16-32 daugther merozoites within the membrane enclosed parasitophorous
vacuole (PV) which is set up by parasites quickly after invasion. Following each replication
cycle (48hr), the parasitophorous vacuole membrane (PVM) and the red blood cell membrane
(RBCM) rupture to release the merozoites through a process called egress (2). These merozoites
then invade new red blood cells. The continuous rounds of schizogeny and egress contribute to
the clinical features of malaria and therefore is of considerable interest for drug and vaccine
development.
The mechanism of parasite egress is finely tuned and regulated as premature egress produces
non-invasive merozoites (2). It follows an inside-out mode, meaning the PVM ruptures prior to
the RBCM (3). Shortly before egress there is an increase in the intra-parasitic Ca2+ concentration
(4). One of the known targets of Ca2+ is the calcium-dependent protein kinase 5 (CDPK5) (5). A
3’5’-cyclic monophosphate (cGMP)-dependent protein kinase (Protein Kinase G- PKG) controls
egress upstream of CDPK5 (6, 17). When PKG is activated, it triggers secretion of organelles
involved in egress and invasion. One of these organelles is exoneme (7) which were discovered
over a decade ago. They were found to contain the serine protease SUB1 and inhibitors of SUB1
blocked both egress and invasion (8).
The serine protease subtilisin-like protease 1 (SUB1) is required for breakdown of PVM and its
substrates (such as the cysteine proteases called SERAs and the merozoite surface proteins
MSPs) are required for RBCM disruption as well (9-10). Conditional knockout (cKO) of SUB1
prevents the degradation of the PVM and hence egress. cKO of SERA6 does not prevent PVM
degradation but prevents RBC cytoskeleton and RBCM degradation preventing egress as well.
cKO of SERA5, another substrate of SUB1 regulates the kinetics of egress [9-10].
SUB1 is synthesized as an 82kDa zymogen in schizonts. In the endoplasmic reticulum (ER), the
zymogen undergoes autocleavage to a 54kDa (p54) form that remains non-covalently bound to
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the cleaved pro-domain (PD) which is inhibitory (9-11). Post ER, the p54 form of SUB1 is
further processed to the active p47 form. It has been shown that this maturation step is dependent
on the aspartic protease plasmepsin X (PM X) (11). Both PM X and SUB1 are stored in
exonemes (11,16,18). Shortly before egress, a PKG dependent phosphorylation event leads to the
discharge of the contents of this organelle into the PV initiating the egress program (7).
Before SUB1 can be activated, the PD has to be removed. For most subtilisins, the PD is
required for folding, autocatalytic activity and is inhibitory until removal (12).
In the apicomplexan Toxomplasma gondii, the micronemal protein TgMIC5 acts as a prodomain
for TgSUB1 (13). Certain features of TgMIC5 are conserved in PfSUB1 PD, and PDs of other
Plasmodium species. Two conserved aspartate and valine residues mediate inhibition of the
TgMIC5 on TgSUB1. Deletions in the N-terminal of the PD portions do not affect inhibition
whereas that in the C-terminal can lead to moderate to severe reductions in inhibition or binding
(13, 14). The C-terminal end therefore seems to be more important for inhibitory functions. A
crystal structure of PfSUB1 was presented providing intriguing insights. Interestingly, 81
residues (termed p9) from the C-terminal end of the PD remained bound and part of it occluded
the active site of the catalytic domain (15). This p9 piece contained all of the conserved parts of
the C-terminal prodomain (13).
It is not known how PM X knock down leads to the accumulation of p54 SUB1 and block of
egress. Is PM X involved in the removal of the inhibitory PD from the p54/PD complex or does
it directly cleave p54 to p47 or both? Understanding the mechanism of action of PM X on SUB1
could provide a new avenue for development of novel antimalarials.
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3.3 RESULTS
Existing antibodies for SUB1 detect the p54 and p47 species [ref] but not the PD. To visualize
the PD, therefore, we epitope tagged it with a triple hemagglutinin (3XHA) tag. To accomplish
this, we designed a plasmid which allowed us to use CRISPR/Cas9 technology to replace the
native copy of SUB1 with a re-codonized version (Figure 1A). In this re-codonized construct, the
3X HA was inserted between the predicted SUB1 signal peptide and the start of the PD, thus
labelling the PD at its N-terminal end. We edited the SUB1 locus in the PM Xapt strain (11),
providing us the ability to track the fate of the PD in the presence or absence of PM X.
Transgenic parasites were obtained within 3 weeks and confirmed by PCR for integration of the
new copy of SUB1 in place of the native copy. The native copy could not be detected by PCR
analysis (not shown). The transgenic parasites replicated at the same rate as the parent strain
(data not shown). In these parasites, correctly processed SUB1 and the tagged PD could be
visualized by Western blotting (Figure 1B).
Interestingly we noticed an accumulation of SUB1 PD upon knock down of PM X suggesting
PM X dependent processing of the PD (Figure 1B). We excised the bands observed from the
Western blot and submitted for mass spectrometry to identify the cleavage site (s) on the PD as
well as the p54. Unfortunately, due to the COVID-19 shut down we have not received the data
backFurther to determine the action of PM X on the PD of SUB1, we employed in vitro biochemical
techniques. We expressed and purified PM X from the mammalian 293T cells. Recombinant PD
(rPD) was purified from E. coli using the constructs illustrated in Figure 2A. Upon incubation
of the recombinant PM X (rPM X) with recombinant rPD, we observed a cleavage of the rPD.
This cleavage was blocked by the PM X inhibitor CHWM-117 implying the cleavage observed
was PM X specific. In a Coomassie gel, we detected the disappearance of the full length (FL)
rPD and the appearance of two cleavage products (~20kDa and < 10kDa) ((Figure 2B top). On
an anti-His Western blot, we detected the disappearance of the FL rPD but did not detect the
~20kDa cleavage product suggesting that this was the N-terminal cleavage product (Figure 2B
bottom). These data suggested that the cleavage was on the C-terminal end. To confirm this, we
proceeded to make different C-terminal truncations of the PD to look for elimination of the
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cleavage site(s). These constructs contained a 3XHA at the N-terminus and a His tag on the Cterminal end (Figure 2A middle and bottom).
We incubated FLrPD_His, 3XHA_DEL1_His and 3XHA_DEL2_His separately with rPM X and
performed Western blots with anti HA and anti His antibodies. With an anti HA antibody, we
detected a decrease in size of the r3XHA_DEL1_His protein but no change in size of the
r3XHA_DEL2_His protein (Figure 2C). This suggested a C-terminal cleavage event. In addition,
We then excised the FL PD and the cleavage products from the Coomassie gel for mass
spectrometry analysis to determine the peptides present in the three species. Interestingly we
obtained high coverage of the FL and both cleavage products. However, when the peptides of
DEL1 and DEL2 were compared to the peptides of the full-length PD, a piece between DEL1
and DEL2 was not detected with any high confidence (data not shown).
We therefore concluded that the cleavage site was between DEL1 and DEL2 or possibly on their
boundaries. Pino et al (16), previously reported that the SUB1 peptide SMLEVENDAE was a
substrate of PM X and that the PM X activity on this substrate was abolished by adding the PM
IX/X inhibitor 49c. Mutating the peptide to SMAAVENDAE abolished cleavage suggesting that
PM X cleavage likely occurs between the L and E residues (P1 and P1’ residues respectively).
Plasmepsin II was shown cleave between Phe33 and Leu34 of hemoglobin [. To this end we
searched the proposed cleavage region for sequences with similar characteristics.
Interestingly, within our narrowed down sequence we found two putative sites (SLLE and
SFLE). Both are missing from the DEL2 mutant explaining the lack of cleavage of this mutant.
DEL1 contains the entire SLLE sequence but only the S of the SFLE, and hence is cleaved,
possibly at the SLLE site. To investigate these two possible cleavage sites, we expressed
and purified single SFAA and SLAA rPD proteins from E. coli. Upon incubation with rPM X,
each individual mutant was still cleaved (Figure 3A). We hypothesized that these could be
redundant or alternative cleavage sites on the PD. We proceeded to make a double mutant
(SFAA+SLAA). Interestingly, this mutant was resistant to PM X cleavage confirming
redundancy or a requirement for cleavage at both sites (Figure 3B).
Next, we investigated if rPM X was able to cleave rSUB1 to its mature form. For this we
incubated rPM X with purified p54/PD complex of rSUB1 from 293Ts and performed Western
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blots. We observed a cleavage of PD, a process sensitive to PM X inhibition. However, we did
not observe a cleavage of p54 to p47 (Figure 4A). We wanted to determine the association
between the PD and the p54/o47 SUB1 proteins in parasites. For this, we immunoprecipitated the
PD with anti HA beads under the presence of various amounts of PM X (+ atc and -atc+117).
The PD was bound to p54 and almost no p54 was observed in the flowthrough (unbound to PD).
Surprisingly, some p47 was bound to the PD even though the majority of it was found in the
flowthrough (unbound) (Figure 4B). Together these data suggest parasite derived or rPM X can
cleave parasite derived PD or rPD.
To determine if the cleavage sites on PD are physiologically relevant, we will introduce a second
copy of SUB1 with various mutations into WT SUB1, and SUB1 KD parasites. These copies
will be integrated in the cg6 locus of the parasites. The second copy of SUB1 contains the Nterminal HA tag on the PD and a V5 tag on the C-terminus of the full protein allowing us to
differentiate between WT untagged protein and the WT or mutant tagged proteins introduced.
We integrated WT, PD SFAA, SLAA and SLAA+SFAA mutants. Since we are unsure of the
targeting signals encoded in the PD, we will not introduce the deletion 1 and 2 mutants. We will
first check if the native SUB1 was processed. Next, we will look for expression of the mutants
and look for their processing to determine if the cleavage sites are physiologically relevant. We
will also determine the trafficking of the SUB1 mutants by fluorescence and electron
microscopy. Further we will test the processing of the PDs in the different SUB1 mutants and if
these mutants can complement the SUB1 KD. These experiments are summarized in Figure 5.

3.4 DISCUSSION
SUB1 proteolytically processes several substrate proteins localized either in the PV space or
GP1-anchored to the outer leaflet of the plasma membrane. These processing events are required
for parasite egress and invasion. In fact, the fully processed SUB1 itself is required for
breakdown on the PVM. SUB1, like many subtilisins is synthesized as a zymogen that
subsequently undergoes processing to become active (. The propiece, referred to here as the
prodomain (PD) is required for folding, activation and inhibition of the cognate enzyme. SUB1
maturation starts with an autocatalytic cleavage in the ER producing a semi-mature form bound
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non-covalently to the cleaved off PD. This is followed by another cleavage that is mediated by
PM X. This second cleavage happens in a post ER compartment, but the exact cellular location is
not known. It is possible that the cleavage happens in the PV after exoneme secretion. However,
compound 1treatment as well as CDPK5 knockdown, both blocking exoneme secretion, do not
block the SUB1 processing suggesting that the cleavage occurs inside the parasite prior to
secretion. Afterall, it is estimated that the time gap between the exoneme secretion and the
breakage of the PVM is less than 10 minutes (3).
The mechanism by which PM X matures SUB1 was investigated in this work. When we knocked
down PM X in parasites, we noticed an accumulation of both the p54 and PD pieces of SUB1. In
vitro rSUB1 is purified as a p54/PD complex. Incubation with rPM X leads to cleavage of the PD
but not p54. rPD from E.coli was cleaved by PM X. We propose a mechanism in which PM X
removes the PD of SUB1, followed by autocatalytic cleavage of the p54 to p47. This second step
can be in cis or trans. In vitro, p82 is always purified as p54/PD with contaminating p47 and
there is a slow conversion of p54 to p47. It is likely slow because of the absence of PM X. It is
conceivable that there is a very low-probability stochastic disengagement of PD from p54
permitting the second cleavage. In parasites however, removal of PD may be a fast process
leading to faster autocleavage. We cannot rule out the possibility of another protease converting
free p54 to p47. However, after extensive proximity labelling experiments with PM X, we did
not identify any possible candidates. It is possible that the expression of PM X is so low that we
are below the sensitivity of detecting neighboring proteases. SUB1 has proven difficult to tag
with BirA. It was facile to tag with it a 3XHA.
The cleavage of the PD in vitro occurs at two sites and either can be cleaved independently. The
cleavage of the two sites likely disrupts the classic 4- strand beta sheet plus 2-antiparallel alpha
helices of PDs. There are two possible consequences of this. One, it may prevent binding of PD
to p54 (14). Secondly, it could lead to a change in the conformation of the inhibitory residues of
PD lodged in the active site. Deletions in TgMIC positions 131-138 lead to a 20 fold decrease in
inhibitory activity compared to WT. The eight amino acids that would be removed by a double
cleavage by PM X could correspond to these residues. In addition, it is possible that the
remaining C-terminal tail carrying the important Asp (p7) and Val (p4) residues is no longer
engaged with active site amino acids.
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An ability to purify p54 without a PD bound to it would help answer the question. Whether the
p54 would fold correctly is unknown since subtilisins can require PD for folding. We have not
been able to purify p54 by itself. However, one can assume that PM X has access to free p54
after it cleaves the prodomain off.
Another form of activation of subtilisins occurs as a result of changes in conformation of the PD
as proteins are trafficked post ER, a mechanism used by prokaryotes dissociates from the
cognate enzyme pH changes that occur in other subtilisins. If this were the case in P.F, we would
see the same amount of PD around irrespective of PM X presence.
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3.6 FIGURES
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Figure 1: PM X mediates the cleavage of the prodomain of SUB1 in vivo
A) Tagging the PD of SUB1 in the Plasmodium falciparum in PM X knockdown strain with a
triple hemagglutinin (3XHA) epitope tag. This illustrates the plasmid used for CRISPR
modification in parasites including the strategy by which it integrates at the native SUB1. SP is
the signal peptide of SUB1 required for proper translocation, PD is prodomain and p54 is semiprocessed SUB1 protein. B) An anti-HA Western blot showing the detection of the prodomian
SUB1 in parasites. Late stage parasites were harvested on a magnetic column and prepped for a
Western blot for the HA signal. SUB1 PD accumulates in parasites upon knockdown (-aTc) and
a combination of knockdown with inhibition (-aTc/117) of PM X. The PD is processed when
PMX is expressed (+aTc).
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Figure 2: PM X cleaves the prodomain but not p54 of SUB1 in vitro. A) Constructs for
purification of Full length PD (FL PD) with a C-terminal his tag. DEL1 and DEL2 refer to the
deletion mutants studied in C and illustrated in D. The arrows on the FL PD indicate the
positions of the deletions created from the C-terminal end. B) Top: A Coomassie blot showing
cleavage of FL PD and inhibition of cleavage PM X by CHWM-117. The black arrow is rPM X,
the red arrow is FL PD and the blue arrows indicate the cleavage products. Bottom: The samples
from the reactions were probed with an Anti-His antibody. It shows a loss in intensity of FL PD
by PM X and reversal by 117. C) Purified deletion mutants of the PD were incubated with rPM
X and probed for the N-terminal HA epitope tag. The blots show a change in size of DEL1 (top)
but not DEL2 (bottom). D) Amino acid sequence of the PD. The red asparagine (N) highlighted
is the end of DEL2 and the red serine highlighted (S) is the end of DEL1. The bolded sequence
represents the predicted region of cleavage from our mass spectrometry and deletion analyses.
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A

B

Figure 3: There are two PM X cleavage sites in the C-terminal end of the PD
A) The cleavage mutants at two distinct sites of the predicted cleavage regions do not
prevent blockage in cleavage (SFLE, SLLE). Top: Coomassie blot showing cleavage FL
cleavage mutant PDs. Bottom: An anti-His Western blot showing cleavage of WT and
SFLE -> SFAA and SLLE -> SLAA single mutant PDs.
B) Double mutant (DM) of SFLE plus SLLE (SFAA + SLAA) blocks processing by PM X.
Top: Construct for purifying DM from E. coli. Bottom: Anti-HA Western showing that
there is no detectable change in the size of the DM implying a block in cleavage.
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Figure 4: rPM X cleaves the rPD from 293T cells and cleavage is inhibited by the PM X
inhibitor CHWM-117 but it does not cleave p54 and p54 is always bound to PD in parasites.
A) Construct for expressing SUB1 in 293Ts. A 6xHis is inserted in the C-terminal end for
purification. B) Anti-HA Western blot tracking rPD shows PM X cleavage that is blocked by
117. rSUB1 was purified from 293T as p54/PD complex. This was incubated with rPM X for 6
hours in PM X buffer. The reaction products were incubated with sample buffer at 99°C for five
minutes before SDS-PAGE to separate the proteins C) Anti-His Western blot showing that there
is no extra cleavage of p54 SUB1 upon incubation of rSUB1 with PM X. D) Anti-HA beads
were incubated with lysate from highly synchronized schizonts in the various conditions shown
(+aTc yields p47 SUB1, -aTc+117 yields p54 exclusively) to bind the HA tagged PD. Then the
beads were washed after incubation and the unbound products are referred to as flow-through
(FT). Anti-SUB1 antibody was then used to detect p54 and p47 in the input and the bound vs
unbound fractions. IN means the input samples, IP is the immunoprecipitated protein,

.
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A. Assessing the cleavage of various mutant PDs by expressing a second copy of
various mutants in WT parasites and assessing processing by Western blotting.
B. Complementation of the SUB1 knockdown strain with WT and PD mutants using
growth assays.
Figure 5: This is a tentative figure to be included in final thesis after COVID-19 lockdown is
over. It will involve confirmation of the cleavage sites that we have discovered in recombinant
assays in malaria parasites.
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Figure 6: Our proposed mechanism by which PM X processes SUB1. Left: in parasites PM X
quickly cleaves the PD of SUB1 allowing a fast, self-processing of the semi pro form of SUB1.
Right: in vitro, since PM X is not available, only a small stochastic falling off of the PD from
p54 SUB1/PD complex would lead to the second auto-processing step. This step is slow and is
what is observed when SUB1 is expressed from mammalian cells.
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METHODS
Cloning the donor plasmid for CRISPR/Cas9 editing of SUB1 locus in PM X-APT strain
To edit the SUB1 locus in order to epitope tag the prodomain, two gblocks (Homo sapiens recodonized) were obtained from IDT. The two gblocks when combined contained the following in
that order
Signal peptide of SUB1-3XHA-Full length SUB1. 500bp of the 3’UTR of SUB1 and ~440bp of
the 5’UTR immediately upstream of the start codon were cloned into the plasmid PM2GT. An
AscI restriction site was inserted in between the RHR and LHR. downstream of the LHR, the
gblock containing the SP, 3XHA and FL SB was cloned into the EagI site.
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ATGATGCTCAATAAAAAAGTTGTTGCTTTGTGCACACTTACCTTACATCTTTTTTGTA
TATTTCTATGTCTAGGAGCGGCCGCGTACCCTTATGACGTTCCAGACTACGCTTATCC
TTACGACGTCCCCGACTACGCGTATCCCTACGACGTTCCTGATTACGCTAAGGAAGT
GAGGTCCGAGGAAAACGGTAAAATCCAGGACGACGCGAAAAAAATTGTGTCTGAAT
TGCGCTTCCTTGAAAAGGTTGAGGATGTTATTGAAAAGTCTAACATTGGCGGGAACG
AGGTAGATGCGGACGAGAACTCCTTTAACCCTGATACGGAAGTCCCCATCGAAGAG
ATTGAGGAGATAAAAATGCGCGAACTGAAAGATGTGAAAGAAGAAAAGAATAAAA
ATGACAATCATAACAATAATAACAACAATATAAGTTCCAGCAGCTCAAGCTCCTCA
AACACGTTTGGGGAAGAGAAGGAGGAGGTTTCAAAGAAGAAAAAGAAGCTGCGCC
TTATAGTTAGCGAAAATCACGCAACCACACCAAGTTTTTTTCAGGAATCTCTGCTGG
AACCGGACGTATTGTCATTTCTCGAGTCTAAGGGCAATCTTAGCAACCTCAAGAATA
TCAATTCTATGATCATAGAGCTCAAAGAGGACACGACCGATGATGAGCTTATTAGCT
ATATCAAAATTCTTGAGGAAAAGGGTGCCCTTATTGAATCCGATAAACTCGTCTCAG
CCGATAACATTGATATCAGCGGGATAAAGGATGCAATCCGGAGAGGAGAAGAGAA
CATTGATGTCAATGATTACAAATCTATGTTGGAAGTAGAAAACGACGCAGAGGATT
ATGACAAGATGTTTGGTATGTTTAATGAAAGTCATGCCGCGACTAGTAAACGAAAA
AGGCATTCCACCAATGAAAGAGGATACGACACATTCAGTAGTCCATCATACAAGAC
TTACTCCAAAAGTGATTACTTGTACGACGATGACAATAACAACAATAATTATTATTA
TTCTCACTCATCTAACGGACACAACAGCAGTTCCAGAAACTCATCCTCTTCCCGGAG
TCGGCCGGGCAAGTATCATTTCAACGACGAGTTCCGAAATCTGCAGTGGGGATTGG
ATCTCTCCCGGCTTGACGAAACCCAAGAACTGATAAATGAGCACCAGGTGATGAGC
ACTAGAATCTGCGTGATAGACAGCGGTATTGACTACAATCATCCAGATCTGAAGGAT
AATATAGAATTGAATCTCAAGGAGCTCCATGGGCGCAAAGGCTTTGATGATGATAA
CAACGGGATTGTCGATGACATTTATGGAGCCAACTTTGTGAATAACTCCGGAAATCC
TATGGATGATAATTACCACGGAACGCACGTATCCGGCATCATAAGCGCCATCGGAA
ACAACAACATCGGGGTAGTCGGAGTTGACGTGAATAGTAAGCTGATCATTTGCAAA
GCCTTGGACGAGCATAAGCTTGGCCGACTTGGCGACATGTTCAAATGCTTGGACTAT
TGCATATCCCGCAATGCGCATATGATCAATGGCTCATTCTCTTTTGACGAATACTCA
GGGATATTTAATTCCTCCGTTGAGTATTTGCAAAGAAAGGGTATTCTCTTTTTTGTAT
CCGCATCAAATTGTAGCCATCCCAAATCTAGTACGCCCGATATCCGCAAGTGCGATC
TGTCCATAAATGCCAAATACCCGCCGATATTGAGCACTGTCTATGATAACGTAATAT
CCGTAGCTAACCTGAAAAAAAATGATAACAACAACCACTACAGCTTGTCTATTAATT
CATTCTACAGCAACAAGTACTGCCAGCTCGCTGCCCCGGGTACAAATATATATAGCA
CGGCGCCCCACAATAGTTACCGGAAGCTTAATGGGACATCCATGGCCGCACCGCAT
GTCGCGGCCATCGCATCCCTCATATTCTCTATCAACCCCGACCTCTCTTACAAAAAG
GTTATCCAAATACTTAAAGATAGTATAGTATATTTGCCAAGCCTCAAGAACATGGTT
GCATGGGCCGGTTATGCCGACATTAACAAGGCCGTAAACTTGGCAATCAAGTCAAA
GAAGACTTATATTAATAGCAATATATCTAACAAATGGAAAAAGAAGAGTAGGTACC
TCCATtga
Blue= Signal peptide, Red= 3XHA, Green= PD, Black= p54, Italics= Alanine linker
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Cloning of sgRNAs for CRISPR/Cas9 modification of SUB1 locus
We used the previously used sgRNA1 (GCATTAACTAGTACATCAAA) [ref] for editing the
SUB1 locus.
Parasite culture, transfections and growth assays
Parasites were cultured as described previously (11).
Prior to transfecting parasites to edit the SUB1 locus, the PM2GT_SUB1_3XHA PD plasmid
was linearized with the AscI restriction enzyme and purified by phenol-chloroform extraction.
50ug of the digested plasmid was co-transfected with 50ug of the sgRNA plasmid into the PM
X-APT strain. 24 hours later, the parasites were put under a BSD+DSM1 selection. The parasites
were maintained in 1uM aTc for the duration of the transfection and culturing of recovered
parasites.
Cloning and purification of rPD and various mutants
Pet28a was digested with NcoI and XhoI. The PD of SUB1, excluding the putative signal
peptide, was optimized for E. Coli expression using the IDT codon optimization tool. This was
then ordered as a gene block (gblock) and cloned into the digested plasmid using Gibson
assembly. The PD fragment was in frame with the His6 epitope tag at the C-terminus before the
T7 terminator. Point mutations were introduced into this plasmid by digesting the WT plasmid
with AhDI. Two complementary sense and antisense oligos primers encoding the desired point
mutation were annealed to create dsDNA using the protocol below. The dsDNA was then cloned
into the AhDI digested plasmid by infusion cloning. Before creating deletion mutants, a triple
hemagglutinin tag (3XHA) was ordered as a gblock and cloned into the NcoI site of FL PD to
create a Pet28a_3XHA_FL PD_His plasmid. Next, the various deletions were amplified from
the gblock and cloned into an empty digested pet28a plasmid. For the double mutant, a gblock
containing both mutations was ordered from IDT and cloned into the digested empty pet28a
plasmid. All plasmids were sequenced and restriction digested for integrity. These plasmids were
then transformed into BL21s for expression using the IPTG system per manufacturers
recommendation.
10ml of starter culture was grown overnight. This was then diluted to a 500ml culture. When the
OD was ~0.6, 100uM IPTG was added and the cultures were harvested the next day. The
cultures were then pelleted. Bacterial pellets were lysed in 100mM Tris, PH8.0 with 0.1% triton
100 and freshly added 0.2g of lysozyme followed by sonication. The lysed bacteria were spun
down at 12000 RPM for 10 mins. The lysate was diluted 20x in 50mM Tris, 100mM NaCl and
passed over a nickel column. A wash was performed with a wash buffer containing 50mM Tris
pH8.0, 100mM NaCl and10mM imidazole. The proteins were eluted with 50mM Tris pH8.0,
100mM NaCl and 500mM imidazole and was then concentrated in 3K cutoff amplicons at 4000g
for 45 mins to yield the final protein used in our experiments.
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The proteins were visualized on a Coomassie stain to assess purity and were also confirmed by
blotting on a Western with anti-his and/or anti-HA antibodies where appropriate.
Purification of recombinant PM X
Purification of rPfPM X as a secreted protein from heterologous expression system was carried
out as described previously with some alterations1. The construct containing a codon optimized
PM X with a C-terminal 8x His tag was a gift from the UCB. Briefly, the FreestyleTM 293-F cells
(ThermoFisher) was transfected with a mixture of DNA and polyethylenimine (PEI) at 1: 3
(w/v). Three days post transfection, the culture supernatant was harvested and partially purified
using the HisTrap Ni Excel Column (GE Healthcare). PM X-containing fractions were further
purified by gel filtration using a Superdex 200 10/300 column (GE Healthcare) in (buffer
recipe?). Finally, samples were stored in buffer containing 25mM Tris pH 8.0, 200mM NaCl,
1mM TCEP, 1% glycerol at -800C until further use.
Purification of recombinant SUB1
SUB1 was purified from 293T cells as we previously described (11)
Cleavage reactions
For the cleavage reaction, substrates were incubated with rPM X in 25mM Tris, 25mM MES,
pH 5.4 for 6 hours at 37°C.
Reagents and antibodies
The Anti-SUB1 antibody was a kind gift of Dr. Michael J. Blackman (The Francis Crick
Institute, London). The Penta-His Tag antibody was ordered from Thermofisher (P-21315). All
primers and gblocks were ordered from IDT (Integrated DNA Technologies). The aTc used was
purchased from Cayman Chemical.

Western blotting
Western blotting was performed as described previously (11)
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CHAPTER 4
Is Plasmepsin IX dependent processing of RAMA required for rhoptry biogenesis in
Plasmodium falciparum?
This chapter is intended to be a brief synopsis on a protein we have predicted to be a substrate of
PM IX and our interest in its function and its cleavage.
4.1 Summary. When the rhoptry protease plasmepsin IX (PM IX) is knocked down in
Plasmodium falciparum, a rhoptry morphogenesis defect is observed which leads to a defect in
invasion and a severe growth phenotype. The two bona-fide substrates of PM IX are rhoptry
associated protein 1 (RAP1) and apical sushi protein 1 (ASP1). However, both of these
substrates are dispensable for parasite growth and therefore do not explain the rhoptry defects.
We have been interested in determining the substrate(s) of PM IX that are involved in rhoptry
biogenesis. To this end, we searched the proteome of P. falciparum for sequences similar in
identity to the cleavage sites on RAP1 and ASP and performed proximity labelling to determine
what PM IX interacted with. We then searched for proteins in this list that were localized to
rhoptries. Next, we looked for evidence of proteolytic cleavage for these proteins. The rhoptry
associated membrane antigen (RAMA) was one of the primary candidates we pursued. RAMA
contains five regions similar to the searched sequence. It has been localized to rhoptries and is
proteolytically processed (1-3). RAMA has been postulated to bind rhoptry cargo in the Golgi
apparatus and translocate them to the rhoptry organelle (1-3). In the rhoptry, RAMA is
proteolytically cleaved at several similar sites but the importance of these events is unknown.
The protease responsible for its cleavage in rhoptries is unknown. Here, we ask whether PM IX
is responsible for RAMA processing. We also investigate if knockdown of RAMA phenocopies
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knockdown of PM IX. We show that processing of RAMA is required for P. falciparum growth
in red blood cells. When malaria parasites infect red blood cells, they go through a process of
cell division. For Plasmodium falciparum this is ~44-48 hours. When the cycle is complete, the
mature parasites, termed schizonts must break down the membranes that encircle them in order
to enter fresh RBCs. The process of entering new RBCs is complex. It involves an initial lowaffinity contact between the parasite and the RBC, a reorientation of the parasite so that its apical
end can form tight junctions with the RBC, an active penetration of the RBC through an actinmyosin motor activity and finally sealing of the RBC and formation of a vacuole around new
invaded parasite. Several organelles including exonemes, micronemes, rhoptries and dense
granules discharge their contents in the process in that order. The rhoptry organelle, which is
apically localized is involved in both the invasion process as well as the process of setting up a
parasitophorous vacuole for export of proteins involved in immune evasion and nutrient
acquisition.
One approach we employed to identify PM IX substrates was proximity labelling with the biotin
ligase BirA. For this, we used CRISPR/Cas9 technology to tag the C-terminal end of the native
PM IX with BirA_3XHA construct. We obtained parasites and used Western blotting to confirm
the PM IX was tagged with the BirA and a 3XHA. Next to determine the activity of the PM
IX_BirA_3XHA, mature schizonts of this strain were harvested. We then performed Western
blots for biotinylated proteins.
PM IX_BirA_3XHA showed biotinylated proteins (Figure A2.1). Unlabeled parasites and PM
X_BirA_3XHA were used as controls (not shown). The biotinylated proteins were
immunoprecipitated with streptavidin and sent for mass spectrometry (MS). After MS, proteins
with similar peptide counts in PM IX and PM X _BirA_3XHA strains were classified as
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background. Similarly, proteins with similar number of peptides in the background parental
strain compared to PM IX_BirA_3XHA were removed. After all these controls, the top hits from
PM IX_BirA_3XHA are summarized in the table 4.1.
4.2 FIGURES

PM X_BirA_3XHA

PM IX_BirA_3XHA

Figure 4.1. PM IX_BirA_3XHA parasites (left) biotinylate proteins in a different pattern than
PM X_BirA_3XHA parasites (right). Schizont stage parasites were harvested and an anti-biotin
Western blot was performed to show the biotinylation of proteins in our PM IX_BirA_3XHA
parasites compared to the PM X_BirA_3XHA control. The bands with the most intensity
correspond to self-labelling of each protein as confirmed by an anti-HA Western blot (not
shown).
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Table 4.1. Proteins identified to interact with PM IX by biotin ligase (BirA)
Gene

# peptides identified

Notes

PM IX

39

Self-labelling

DPAP3

24

Involved in invasion

RALP1

14

We tagged this gene with
3XHA but did not find the
protein on Western blot

ROP14

10

Not essential

ASP

5

Not essential

PF3D7_0403200

2

Conserved, unknown function

Of the top hits, ROP14, ASP are dispensable (4). RALP1 is predicted to be essential. We created
a RALP1_APT strain and knocked down RALP1. We were unable to observe the knockdown by
Western blot. However, about a 30% growth defect was observed after one cycle of parasite
growth. We aim to clone this strain in order to create non-mixed populations that will allow for
further. This is ongoing work.
A second approach we employed was to search the proteome of P. falciparum for the protein
motif pattern [D/E]S[F/I]L[E/Q] which is the cleavage sites for RAP1 and ASP. Forty-two
proteins had one or more of this motif in its sequence. The top hit, with 5 motifs is the Rhoptry
Associated Membrane Antigen (RAMA) (table 4.2)
To determine the essentiality of RAMA, we employed the TetR-DOZI aptamer system that we
used for PM IX and PM X (3). We were not able to detect RAMA protein by Western blotting.
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However, when aTc was removed from culture medium, implying a knockdown in RAMA
expression, we saw a growth defect in parasites in the first cycle suggesting that it is essential
(Figure A2.2). In fact, another group found the same phenotype upon deleting one of the exons
of RAMA (1).

Figure 4.2. RAMA is essential for parasite growth. Synchronized ring stage RAMA-aptamer
parasites were washed off aTc and then either supplemented with aTc or not (aTc and No aTc
respectively). Parasitemia was assessed by flow cytometry after one cycle of growth.
More interestingly for us, we wanted to know if RAMA processing is necessary for its function.
To this end we cloned a re-codonized wildtype and a proposed cleavage mutant form of RAMA
and transfected those into the RAMA knockdown strain. Each of the second copies were tagged
with a paramyxovirus of the simian virus 5 sequence (V5) at the C-terminal end to distinguish
them from native RAMA which we tagged with a triple hemagglutinin tag.
We integrated these plasmids into the cg6 locus such that every parasite had one copy of either
the wildtype or cleavage defective RAMA mutant. Upon removal of aTc, when native RAMA is
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not expressed, the WT second copy rescued growth by ~70%. However, the single cleavage
mutant only rescued ~ 20% of the growth defect similar to not having a second copy of RAMA
(Figure 4.3A, B). These data suggest that this is cleavage is important for RAMA function. We
are yet to confirm expression of the second copies of the RAMA protein and so no conclusions
can be drawn. It is possible that the mutant is not expressed.
A

B

Figure 4.3. Wildtype but not cleavage-mutant RAMA can rescue RAMA growth phenotype. (A)
The constructs for transfecting the second copies of either wildtype (top) of an SFLQ to SFAA
cleavage mutant. (B) A comparison between the ability of the wildtype (WT) RAMA to rescue
the growth defect vs the mutant RAMA (MUT). Ring stage parasites were wash off aTc and then
put back in culture with or without aTc and parasitemia was assessed by flow cytometry after
one cycle.
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Table 4.2. Proteins identified to contain the putatative PM IX cleavage sites
Gene ID

Product Description

PF3D7_0707300
PF3D7_0809100
PF3D7_0103300
PF3D7_0108700
PF3D7_0311300
PF3D7_0400200
PF3D7_0412400
PF3D7_0510400
PF3D7_0522800
PF3D7_0524800
PF3D7_0528100
PF3D7_0621000
PF3D7_0704100
PF3D7_0706100
PF3D7_0726100
PF3D7_0729300
PF3D7_0900100
PF3D7_0910500
PF3D7_0926900
PF3D7_1011700
PF3D7_1020600
PF3D7_1027000
PF3D7_1134200
PF3D7_1200100
PF3D7_1221300
PF3D7_1233600
PF3D7_1302800
PF3D7_1305300
PF3D7_1340300
PF3D7_1402700
PF3D7_1405800
PF3D7_1410400

rhoptry-associated membrane antigen
erythrocyte membrane protein 1, PfEMP1
conserved protein, unknown function
secreted ookinete protein, putative
phosphatidylinositol 3- and 4-kinase, putative
erythrocyte membrane protein 1 (PfEMP1), exon 2, pseudogene
erythrocyte membrane protein 1, PfEMP1
PDCD2 domain-containing protein, putative
pre-mRNA-splicing factor BUD31, putative
ubiquitin fusion degradation protein 1, putative
AP-1 complex subunit beta, putative
conserved Plasmodium protein, unknown function
conserved Plasmodium membrane protein, unknown function
conserved Plasmodium protein, unknown function
Plasmodium exported protein, unknown function
60S ribosomal export protein NMD3, putative
erythrocyte membrane protein 1, PfEMP1
DNA repair protein REV1, putative
replication termination factor, putative
DNA repair protein RAD23, putative
conserved Plasmodium membrane protein, unknown function
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
erythrocyte membrane protein 1, PfEMP1
conserved Plasmodium protein, unknown function
asparagine and aspartate rich protein 1
40S ribosomal protein S7, putative
translational activator GCN1, putative
nucleolar complex protein 2, putative
U2 snRNP-associated SURP motif-containing protein, putative
ribosome biogenesis protein BOP1, putative
rhoptry-associated protein 1
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Match
Count
5
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

PF3D7_1426500
PF3D7_1430700
PF3D7_1431400
PF3D7_1433700
PF3D7_1440800
PF3D7_1442700
PF3D7_1459100
PF3D7_1468000
PF3D7_1474600
PF3D7_1478700

ABC transporter G family member 2
NADP-specific glutamate dehydrogenase
surface-related antigen SRA
conserved Plasmodium protein, unknown function
major facilitator superfamily domain-containing protein, putative
conserved Plasmodium protein, unknown function
GTP-binding protein, putative
conserved Plasmodium protein, unknown function
vacuole membrane protein 1, putative
Plasmodium exported protein, unknown function, pseudogene

1
1
1
1
1
1
1
1
1
1
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CHAPTER 5
Conclusions to be drawn from the thesis work presented and future directions
We have discovered interesting roles of two aspartic proteases in malaria biology. We have
shown that PM X is druggable and therefore a possible antimalarial target. The fact that it is
expressed in other stages of the life cycle makes it even more interesting as drugs against it could
cure patients as well as block transmission by killing mosquito stages.
Many questions still intrigue us. We have shown that PM IX is involved in processing of an
unknown protein that is involved in rhoptry biogenesis. This was unexpected since PM IX is
expressed about only 4 hours before parasite egress and rhoptry synthesis starts about 20 hours
prior. The defective rhoptries we see are of two types. The first type has no neck regions and
therefore cannot attach to the apical end of parasites and so are not functional. The second type
also do not make apical attachments but in addition seem to be missing components as they are
electron lucent. Why there is a dichotomy in phenotypes is still unknown. Since we are not
making complete knockouts of PM IX, it is possible parasites have different amounts of the
protein and this explains the discrepancy. This theory is not well supported by our data because
we can see both types of rhoptries in the same merozoite in schizonts. We have attempted to
identity the protein (s) that PM IX cleaves by proximity labelling as well as searching the
proteome for sequences similar to the PM IX cleavage site on RAP1. In proximity labelling
experiments, our top hits were rhoptry associated leucine-zipper protein 1 (RALP1) and rhoptry
neck protein 14 (ROP14). Piggy back mutagenesis studies by the John Adam’s group show that
ROP14 is not essential. We created a knockdown of RALP1 but did not see a significant growth
defect (data not shown). When searching the proteome for RAP1-type cleavage sequence, the top
hit was RAMA with 5 of those sequences. As presented in the RAMA chapter, we show that this
protein is essential and we will characterize the phenotypes and importance of the cleavage.
We have now created a strain of parasites in which PM IX is tagged with a more robust version
of the biotin ligase called BioID2. This will enable the discovery of proteins expressed at lower
levels. Together with the original PM IX BioID strain, we should be better able to define the
proteome of rhoptries. From that data we can predict possible PM IX substrates and validate
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these in parasites. It is possible that the cleavage of more than one substrate is responsible for the
PM IX phenotype and that an accumulation of such unprocessed products determines the fate of
rhoptries. Assessing such emergent effects will be difficult since we are currently limited to only
4 drug selection markers in parasites, one of which is already present in the PM IX strain.
Plasmepsin X was more difficult to characterize as we could not determine if the knockdown
strain had an egress or invasion defect. As it turned out, using video microscopy, the parasites
had difficulty egressing and those that were able to at the correct time had an invasion defect as
well. With electron microscopy we were able to colocalize PM X with the serine protease SUB1
which was discovered to be important a decade before. SUB1 has one puzzling feature. Like
most subtilisins, it autocleaves a part of it called the prodomain which remains bound to the
active enzyme non-covalently (12). Laboratories that expressed this enzyme were interested in
crystalizing it in hopes of discovering compounds that would block its activity. Frustratingly,
they could not make homogenous SUB1 since it always purified as two species, the intermediate
inactive form (the dominant fraction) and a small fraction of the active form. What could
possibly have been converting it to the active form? Was it a second autocatalytic process? If so,
why did it take days to self-convert? That did not seem physiologically relevant. Inhibitors of
SUB1 blocked both egress and invasion reminiscent of the PM X knockdown. We hypothesized
that PM X was responsible for conversion of the intermediate SUB1 to the mature, active form.
When we knocked down PM X, SUB1 accumulated in the mature form and substrates of SUB1,
responsible for both egress and invasion remained unprocessed. In fact, not a single parasite
egressed out of the 300 we monitored when we combined a PM X knockdown with inhibition of
the low levels of PM X available.
The next interesting questions for us was exactly the mechanism but which PM X was involved
in SUB1 processing. We had three models for would be happening in parasites as summarized
next.
1. PM X removes the prodomain of SUB1 and cleaves intermediate SUB1 to mature SUB1
2. PM X removes the prodomain of SUB1 and SUB1 autocleaves to its mature form
3. The prodomain of SUB1disengages with the intermediate form of SUB1 (by changes in
environment e.g. pH) and PM X cleaves intermediate SUB1 to mature SUB1
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Our data suggests that mechanism 3 is unlikely because we see an accumulation of the SUB1
prodomain when PM X is unavailable.
Next, we wanted know where PM X was cleaving the prodomain and our data suggest two
places which both get cleaved. This cleavage likely disrupts the structure of the prodomain and
either prevents binding or relieves the inhibitory effect of the prodomain, the next question we
want to answer.
Altogether, this thesis document reveals key functions of PM IX and PM X, some glaring
questions still remain. What does PM IX cleave that is important in rhoptry biogenesis? When
does rhoptry biogenesis start and why is that cleavage so important for the process? We have
noticed that cleavage of the rhoptry protein RAMA could be important and that suggests that
processing of key rhoptry proteins could essential for correct biogenesis. Tracking an early
synthesized rhoptry protein could go a long way in enabling us determine synthesis of this
mysterious organelle. One interesting experiment we would like to perform is to determine what
RAMA interacts with. For this we would immunoprecipitated wildtype RAMA and cleavage
mutant RAMA and determine if there is any difference in proteins obtained. We would expect
that upon cleavage of RAMA, cargo bound to it would diffuse away and so the wildtype IP
would contain fewer proteins. When RAMA cannot be cleaved, we expect the cargo bound to it
to still be bound upon IP
What else is in exonemes vesicles with PM X and SUB1? Are any of these involved in SUB1
maturation? Are any involved in egress and invasion? When do exonemes get synthesized? What
is the difference in trafficking of proteins between rhoptries and exonemes if all organellar
proteins go through the same secretory pathway? I attempted to find the sequence that specified
translocation to exonemes using truncations of the prodomain of SUB1 or PM X fused to GFP
but the results were inconclusive. I propose using a stronger promoter such as AMA1 in the
future for such studies in order to be able to visualize the GFP. Alternatively, the much brighter
protein neon-green can be used instead of GFP. This would in fact allow visualization by live
microscopy the expression and location of various truncation mutants over time. One other
question about PM X is its prodomain region. Is it truly a prodomain? Would it inhibit activity of
the catalytic domain of PM X? How would one assay this? I propose that the prodomain of
SUB1 be used as the bona fide substrate of PM X instead of synthetic peptides that are currently
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being used. Alternatively, a very specific PM X cleavage peptide could be created. One can do
this by creating a random phage library and assaying for the specificity of PM X.
APPENDIX
A.1 What is the role of PM V in parasite biology?
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A1.1 Introduction
Upon infecting a red blood cell (RBC), the malaria parasite Plasmodium falciparum drastically
remodels its host by exporting hundreds of proteins into the RBC cytosol. This protein export
program is essential for parasite survival, hence export-related proteins could be potential drug
targets. One essential enzyme in this pathway is plasmepsin V (PM V), an aspartic protease that
processes export-destined proteins in the parasite endoplasmic reticulum (ER) at the Plasmodium
export element (PEXEL) motif. Despite long-standing interest in PM V, functional studies have
been hindered by the inability of previous technologies to produce a regulatable lethal depletion
of PM V. To overcome this technical barrier, we designed a system for stringent posttranscriptional regulation allowing a tightly controlled, tunable knockdown of PM V. Using this
system, we found that PM V must be dramatically depleted to affect parasite growth, suggesting
the parasite maintains this enzyme in substantial excess. Surprisingly, depletion of PM V arrested
parasite growth immediately after RBC invasion, significantly before the death from exported
protein deficit that has previously been described. The data suggest that PM V inhibitors can halt
parasite growth at two distinct points in the parasite life cycle. However, overcoming the functional
excess of PM V in the parasite may require inhibitor concentrations far beyond the enzyme’s IC50.
Keywords: Aspartic protease, malaria, CRISPR/Cas9, knockdown, protein export, dense granule
Malaria remains a scourge of the developing world, causing nearly 500,000 deaths per year, with
the overwhelming majority due to Plasmodium falciparum infection (1) While the life cycle of P.
falciparum includes replication in both the liver and blood, symptomatic human disease is caused
by infection of red blood cells (RBCs) (2). Upon infection of a host RBC, the parasite executes a
dramatic program of protein export, sending hundreds of proteins through the secretory system,
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across the surrounding vacuole (parasitophorous vacuole, PV) through a parasite-encoded
translocation complex called PTEX, and into the host cytosol (3,4). These exported effectors
drastically remodel the host cell, setting up new solute permeability pathways, modifying the RBC
shape and rigidity, and reconstituting trafficking machinery in the RBC cytosol to send parasiteencoded adhesins to the RBC surface (3,4). These adhesins mediate binding of infected RBCs to
vascular endothelia allowing parasites to avoid splenic clearance. Adherent parasites in the brain
can cause vascular blockage leading to death in severe cases (2).
Due to the central role of protein export in the survival and virulence of P. falciparum, there has
been interest in this pathway as a source of potential drug targets. One essential enzyme in the
pathway is the parasite aspartic protease plasmepsin V (PM V) (5,6). PM V processes exported
proteins in the parasite ER by cleaving them co-translationally in a variant signal recognition
particle complex (7) Cleavage occurs at the conserved amino acid motif RxLxE/Q/D, termed the
Plasmodium export element (PEXEL) (8-12). PM V is highly specific for RxL in the PEXEL and
cleaves after the leucine (10, 13, 14). PEXEL processing is a critical step in protein export, as
mutations in PEXEL that block PM V processing also block protein export (11,12). Furthermore,
processing of PEXEL proteins is likely an essential function in the parasite, as PM V is essential
for survival in both P. falciparum and the related rodent parasite P. berghei, and treatment with a
PEXEL peptidomimetic is lethal to intraerythrocytic parasites (6, 15-17)
A number of tools have been used to study PM V, including peptidomimetic inhibitors that block
its function in vitro and are lethal to parasites in culture, a DiCre-mediated inducible excision of
the gene, and crystallographic studies of P. vivax PM V (6, 16-18). However, study of PM V
function has been hindered by an inability of previous depletions to yield a phenotype in RBC
culture. The most robust knockdown described used the glmS ribozyme system, reducing PM V
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levels 10-fold with no measurable effect on parasite growth or PEXEL processing (7,16). Here,
we sought to apply the recently described TetR-DOZI aptamer system for stringent and tunable
regulation of PM V (19) This system can deplete a reporter gene 45 to 70-fold when aptamers are
installed in both the 5’ and 3’ untranslated regions (UTRs) of the target gene (19). However,
cloning such a construct in traditional plasmid systems requires the assembly and maintenance of
large circular plasmids that are prone to deletions and vector rearrangements during propagation
in E. coli (20). To overcome this technical challenge, we assembled a number of tools for genetic
manipulation onto a previously described linear vector. Using this new vector system, we achieved
substantially greater depletion of PM V than had been reported. By tuning the degree of
knockdown, we confirmed that PM V is maintained in substantial excess during RBC infection
and must be suppressed to nearly undetectable levels to affect parasite growth. Finally, we found
that PM V-depleted parasites die immediately after invasion in a manner distinct from that of
disruptions of other protein export machinery, suggesting PM V may have additional roles beyond
those previously described.
A1.2 Results.
Construction of a linear vector for aptamer knockdowns
To overcome the challenges associated with maintaining P. falciparum genomic material in
circular plasmids, we utilized the pJAZZ linear vector system (20) as a chassis for DNA assembly.
This system has previously been used to manipulate large [A+T]-rich genomic fragments,
including those derived from the rodent malaria parasite, P. berghei.20,21 We constructed a plasmid
(“pSN054”) to allow facile cloning, endogenous tagging, robust regulation of expression and
inducible knockout of P. falciparum genes (Figure A1.1A, Figure A1.S1). pSN054 has the
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following features: a single 5’ aptamer, 10x array of 3’ aptamers, regulatory protein (TetR-DOZI
complex) (19), parasitemia-tracking component (Renilla luciferase), drug selection marker
(Blasticidin S deaminase) (22), cassette for generation of sgRNA for CRISPR/Cas9 genome
editing, cloning sites for inserting homologous sequences for genome repair, modularized affinity
tags for tagging genes of interest at the N- or C-terminus, and loxP sites for gene excision (Figure
A1.1A).
To utilize pSN054 for genome editing, a gene of interest must be recodonized to replace the current
gene, preventing aberrant homologous repair from truncating the construct. To facilitate repair,
400-600bp of homologous sequence corresponding to the 5’ and 3’ UTR of a gene, are cloned into
the FseI and I-SceI restriction sites respectively (Figure A1.S1). This intermediate vector can be
used to create gene knockouts since it does not possess the coding sequence of the gene of interest.
A subsequent Gibson assembly inserts the coding sequence of the gene. pSN054 contains the 2A
skip peptide (23) such that cloning into the AsiSI site produces a protein with no tag on the Nterminus. If an N- or C-terminal tag is desired, the relevant restriction site is used for gene insertion
(Figure A1.S1). This donor plasmid can be adapted for use with the T7-RNAP CRISPR/Cas9
system (24) by cloning an sgRNA into the I-ppoI site. Alternatively, a U6 promoter-containing
gRNA plasmid (25) can be used and co-transfected with a finished pSN054 donor plasmid.

TetR-DOZI aptamer system for tagging and regulation of PM V
To apply pSN054 to PM V, we cloned pieces of the 5’ UTR and 3’ UTR into FseI and I-SceI
respectively, as well as a recodonized PM V coding sequence into plasmid cut with AsiSI and
133

BsiWI (Figure A1.1B). This plasmid enabled us to replace the endogenous PM V gene with a
FLAG-tagged recodonized PM V flanked by aptamers. The construct was co-transfected into the
P. falciparum strain NF54attB (26) (referred to as “NF54” throughout) along with a separate gRNAcontaining plasmid pAIO (25), and parasites selected and cloned. Incorporation of the construct
into the genome was verified by Southern blot (Figure A1.2A). Expression of a FLAG-tagged
protein of the expected size was verified by western blot (Figure A1.2B). Similarly, a western blot
with anti-PM V verified that modification of this locus did not substantially change PM V
expression levels of the edited line relative to the parent (Figure A1.2C).
PM V is maintained in substantial excess during infection
We then utilized the TetR-DOZI aptamer system to post-transcriptionally deplete PM V.
Knockdown was initiated by washing out anhydrotetracycline (aTc) from young ring-stage
parasites in RBC culture. In the absence of aTc, (Figure A1.2E). This confirms previous reports
that PM V is essential for intraerythrocytic growth (6, 16, 27) and showcases the ability of the
TetR-DOZI aptamer system to drive more substantial depletion of proteins than previously
possible.
We next utilized the tunability of the TetR system to determine the amount of PM V required for
parasite survival. To this end, we titrated aTc levels and followed parasite growth by flow
cytometry. Parasites maintained in 3 nM aTc or above grew normally. Parasites maintained in
DMSO or 1 nM aTc arrested by 96h, while parasites maintained in 2 nM aTc survived an additional
cycle before arresting at 120h (Figure A1.3A). Given this, we sought to quantify the PM V
depletion necessary to affect parasite growth. We synchronized parasites and washed out aTc from
cultures containing predominantly young ring-stage parasites, then harvested samples for western
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blot at 72h following washout to compare the PM V levels in parasites that would go on to survive
another cycle (2 nM aTc) to those that would arrest in the next 24h (1 nM aTc). Over three
independent experiments, we estimate that approximately 8% of wildtype PM V (2 nM aTc)
supports another cycle of growth, while 3% (1 nM aTc) was insufficient and led to death upon
reinvasion (Figure A1.3B, C). Since these parasites presumably divide their PM V, diluting it
among their daughter cells before the next cycle begins, our data suggest that PM V is maintained
in enormous functional excess in parasite culture, with perhaps less than 1% of wildtype PM V
likely sufficient to support growth in parasite culture.
PM V-depleted parasites arrest early in life cycle
Given the canonical role of PM V in protein export, we expected PM V depletion to phenocopy
disruption of other critical export machinery such as components of the Plasmodium translocon
for exported proteins (PTEX) which mediates translocation of effectors across the PV membrane.
(3, 28, 29). PTEX components Hsp101, PTEX150 and EXP2 are all essential in parasite culture,
and previously described depletion of any of these caused parasite arrest during the early
trophozoite stage (30-32). Therefore, we were surprised to find that PM V depletion caused growth
arrest very early in the intraerythrocytic development cycle, arresting as “dots” shortly after
invasion (Figure A1.4A, B). Arrested parasites were further investigated by transmission electron
microscopy and were found to have gross structural abnormalities (Figure A1.4C). PM V-depleted
parasites generally showed more electron density throughout the parasite cytosol, failure to expand
much beyond the size of merozoites, and large unidentified vacuolar structures within the parasite.
In contrast, when parasites were fixed as schizonts from the preceding cycle, there was no obvious
morphological defect (Figure A1.4D). This suggests that PM V plays some critical role(s) in
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successfully initiating the intraerythrocytic development cycle, distinct from its canonical protein
export role.
To assess whether PEXEL processing was defective at the time of parasite death, we purified PM
V-depleted schizonts and allowed them to invade fresh RBCs for four hours, then probed the status
of the early exported protein RESA by western blot and immunofluorescence. PM V depletion led
to an accumulation of unprocessed RESA as well as a corresponding defect in RESA export to the
surface of the infected RBC (Figure A1.S4).
PM V inhibitors kill parasites at multiple points in the intraerythrocytic development cycle
Previous work indicated that PM V inhibitors were lethal at the ring-trophozoite transition,
consistent with depletion of PTEX components (17). Since this differs from our finding that PM
V depletion arrests parasite growth early after invasion, we sought to recapitulate the previously
described early trophozoite death as well as our early post-invasion death with the peptidomimetic
PM V inhibitor WEHI-842 (17, 18). We treated synchronized ring-stage parasites or schizonts
with 5 µM WEHI-842 for an 8-hour window, then monitored parasites by thin smear. We found
that ring-stage parasites treated with WEHI-842 arrested as early-trophozoites as previously
described (Figure A1.5A). However, parasites treated with WEHI-842 beginning in schizogony
arrested immediately after invasion, as was seen in our genetic PM V depletion line (Figure
A1.5B). Taken together, our data suggest that parasites are sensitive to PM V inhibition at two
points during asexual growth in RBCs. The first is immediately after invasion. The second is in
early trophozoites and is phenocopied by PTEX disruptions.
A1.3 Discussion
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We report the first regulatable knockdown that lowers PM V levels enough to reveal a lethal
phenotype. This work overcomes the technical limitations of past knockdown systems by utilizing
the TetR system with aptamers on both the 5’ and 3’ end of the gene of interest. This manipulation
was facilitated by the plasmid described here, pSN054, which enables a suite of previously
described genetic tools to be utilized with relative ease for gene editing to achieve protein tagging,
regulation of gene expression, parasite growth monitoring and inducible knockout as required.
An unexpected result is that PM V depletion does not phenocopy the disruption of PTEX
components (30-32). The fact that the early death phenotype described here is not seen in
disruption of other export machinery suggests that PM V has a role independent of protein export
that is essential for parasite survival in RBCs. A reasonable hypothesis is that this role could be
the cleavage of a critical substrate early in the life cycle to allow it to perform an essential activity.
In this case, the substrate would likely be acting within the parasite or parasitophorous vacuole,
since disruption of Hsp101 function with a destabilization domain blocked nearly all exported
effectors within the vacuole but only arrested growth in early trophozoites (30). One possible
source of essential PM V substrates is parasite secretory organelles called dense granules that are
involved in establishing the PV (35). In the Apicomplexan parasite Toxoplasma gondii, the PM V
ortholog Asp5 primarily cleaves dense granule effectors at a PEXEL-like sequence near their Ntermini (34, 35). Similarly, in Plasmodium, the dense granule protein RESA is cleaved at a
“relaxed” PEXEL sequence of RxLxxE (10) by PM V (Figure A1.S4). It is then rapidly secreted
into the PV during parasite invasion (10). While RESA is dispensable for intraerythrocytic growth
(36) other PM V substrates may follow a similar trafficking route and may be required early in the
intraerythrocytic development cycle. Alternatively, early death could be a non-specific result of
PM V deficiency, such as a buildup of uncleaved PEXEL proteins in the ER. Consistent with this,
137

treatment with the canonical ER-stress inducer DTT arrested growth in P. falciparum with similar
morphology by Giemsa stain to that caused by PM V depletion described here (37).
One encouraging note for the development of PM V inhibitors as antimalarials is our finding that
PM V inhibition can lead to parasite death at two distinct points within intraerythrocytic
development. Knockdown of PTEX components seems to cause growth arrest only at the early
trophozoite stage in blood-stage parasites (30-32). Due to this, drugs inhibiting the function of
PTEX components may take up to a full intraerythrocytic cycle (48 hours) to reach the point in the
cycle where growth arrest occurs. In contrast, PM V inhibitors may arrest growth more quickly by
acting upon intraerythrocytic parasites at more than one point in the life cycle. Recent work has
also shown that PM V inhibitors can block development of early-stage gametocytes, and have a
transmission-blocking effect (38). Together, these findings bolster the case that PM V inhibitors
can have properties in line with the target antimalarial profiles put forward by the Medicines for
Malaria Venture (39). However, these beneficial characteristics are counterbalanced by our finding
that PM V must be suppressed to barely detectable levels to affect parasite growth. Peptidomimetic
inhibitors of PM V that have been developed are generally greater than 100-fold less potent in
culture than on isolated enzyme (16, 17, 40). It has been presumed that potency against parasites
is limited by cellular permeability. Our functional genetics data would suggest that an additional,
and possibly major, component of the potency drop-off is the need to inhibit nearly all the cellular
enzyme to kill parasites. It is possible that a potent compound with good biochemical and
pharmacokinetic properties could overcome this barrier to sufficiently inhibit PM V during human
infection to achieve high antimalarial efficacy.
Taken together, our study provides further data on the proposed antimalarial drug target
plasmepsin V. Future work is needed to determine if PM V is maintained at excessive levels in
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vivo as it is in vitro, and to elucidate the cause of growth arrest after invasion in PM V-depleted
parasites.

A1.4 Materials and Methods
Parasite lines and culture
P. falciparum strain NF54attB (referred to as NF54 throughout) was used as a parent strain for
transfections (26) Asexual parasites were cultured in RPMI 1640 (Gibco) supplemented with
0.25% (w/v) Albumax, 15mg/L hypoxanthine, 110mg/L sodium pyruvate, 1.19g/L HEPES,
2.52g/L sodium bicarbonate, 2g/L glucose, and 10mg/L gentamycin. Deidentified RBCs were
obtained from the Barnes-Jewish Hospital blood bank (St. Louis, MO), St. Louis Children’s
Hospital blood bank (St. Louis, MO), and from American Red Cross Blood Services (St. Louis,
MO).
Generation of knockdown line
The construct for aptamer regulation of PM V was constructed using pSN054, described above.
The right homologous region (3’ UTR) was amplified from NF54 genomic DNA using primers
AGTGGTGTACGGTACAAACCCGGAATTCGAGCTCGGGGAATCAACATAGAAACGTTAAAG
GATTGGGTATTAGACCTAGGGATAACAGGGTAATGTACTAGGTCATTTTCTTTATTTTAC,

and

and cloned into

the I-SceI site using Gibson Assembly (NEB). The left homologous region (5’ UTR) was
amplified from NF54 genomic DNA using primers
TTGGTTTTCAAACTTCATTGACTGTGCCGACATTAATTTGTGTAACATATAAATATGTAG

and

AAGTTATGAGCTCCGGCAAATGACAAGGGCCGGCCCTTTCCTTAAAAAATAATTATTGAT,
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and cloned

into the FseI site. PM V was codon-optimized for expression in Saccharomyces cerevisiae and
synthesized as gene blocks by Integrated DNA Technologies (Coralville, IA) then cloned into the
vector at the AsiSI and BsiWI sites. The plasmid was grown in BigEasy Electrocompetent Cells
(Lucigen) with 12.5 µg/mL chloramphenicol and 0.01% (w/v) arabinose.
CRISPR/Cas9 editing was performed as previously described (25). Guide RNA sequences were
inserted into the pAIO vector by annealing oligonucleotides of the sequences
ATTAAGTATATAATATTTGTAATGGTTGTAAAGATTGGTTTTAGAGCTAGA and
TCTAGCTCTAAAACCAATCTTTACAACCATTACAAATATTATATACTTAAT and
inserting them into BtgZI-cut pAIO by In-Fusion HD Cloning (Clontech). pAIO was maintained
in XL10 Gold cells (Agilent Technologies). Bold sequences represent the gRNA site.
For each transfection, 100 µg of donor vector and 50 µg of pAIO were transfected into early
ring-stage parasites in 2mm gap electroporation cuvettes (Fisher) using a BioRad Gene Pulser II.
Transfectants were maintained in 0.5 µM anhydrotetracycline (aTc; Cayman Chemical) and were
selected beginning 24-hours post-transfection with Blasticidin S (2.5 µg/mL; Fisher). Parasites
were obtained from several independent transfections and clones obtained by limiting dilution.
Validation of PM VAPT line
Proper integration of our construct was verified by Southern Blot as in (24). For a probe, the
right homologous region was amplified from NF54 genomic DNA using primers described
above.
To verify tagging of protein, schizonts of NF54 and PM VAPT were first synchronized by
purifying on magnetic columns (Miltenyi Biotech) then allowed to invade fresh uninfected RBCs
for 3 hours before remaining schizonts were cleared with 5% sorbitol. Parasites were then
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allowed to progress for 40h, then RBCs lysed with cold PBS + 0.035% saponin. Samples were
centrifuged to pellet parasites and remove excess hemoglobin, then parasites lysed in RIPA
(50mM Tris, pH 7.4; 150mM NaCl; 0.1% SDS; 1% Triton X-100; 0.5% DOC) plus HALTProtease Inhibitor Cocktail, EDTA-free (Thermo Fisher). Lysates were centrifuged at high speed
to pellet and remove hemozoin. Cleared lysates were then diluted in SDS sample buffer (10%
SDS, 0.5M DTT, 2.5mg/mL bromophenol blue, 30% 1M Tris pH 6.8, 50% glycerol) and boiled
for 5 minutes. Lysates were separated by SDS-PAGE, then transferred to 0.45 µm nitrocellulose
membrane (BioRad). Membranes were blocked in PBS + 3% bovine serum albumin, then probed
with primary antibodies mouse anti-PM V 1:25 (41) or anti-FLAG 1:500 (M2, Sigma), and
rabbit anti-HAD1 1:1000.42 Membranes were washed in PBS + 0.1% Tween 20, then incubated
with secondary antibodies goat anti-mouse IRDye 800CW 1:10,000 (Licor) and donkey antirabbit IRDye 680RD 1:10,000 (Licor). Membranes were then washed in PBS + 0.1% Tween 20
and imaged on a Licor Odyssey platform.
Assessment of knockdown
To assess the effect of PM V knockdown on parasite growth, aTc was removed from cultures by
washing 3 times for 5 minutes each in media without aTc, then either 500nM aTc (“+ aTc”) or
DMSO (“- aTc”) was added and parasites split into 1mL triplicate cultures for each condition.
Parasite growth was monitored daily by flow cytometry (BD FACSCanto) using acridine orange
(1.5 µg/mL in PBS). Parasites were sub-cultured every 48 hours to prevent overgrowth.
“Cumulative parasitemia” was back-calculated based on the sub-culture schedule. Flow
cytometry data is plotted with each point representing the mean of three technical replicates with
error bars showing the standard deviation. Experiments were done three times unless otherwise
noted.
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For titrations of aTc, parasite cultures were washed as above to remove aTc, then cultures were
maintained in media containing the shown concentrations of aTc or DMSO (aTc stocks were
diluted to ensure each culture received equal volumes of the solvent DMSO in order to attain the
desired final aTc concentration). To determine the effect of aTc concentration on PM V levels,
cultures were prepared as above, and samples taken for western blot 72 hours after aTc was
removed. Sample preparation and western blotting was done as above (see Validation of PM
VAPT line). To quantitate PM V titration blots, the 500nM sample was diluted out by factors of
two to draw a standard curve correlating PM V signal to relative amount of the 500nM sample
(see Figure A1.S3). Blots were quantitated using Licor Image Studio. The experiment was
performed three times and the mean for those three experiments is plotted with error bars
representing the standard error of the mean.
WEHI-842 treatment.
]NF54attB parasites were synchronized to within 3 hours as above (see Validation of PM VAPT
line above, paragraph 2). Then either 5 µM WEHI-842, or an equal volume of DMSO was added
to late rings (15h after invasion initiated; parasites 12-15h old), or late trophozoites (44 hours
after invasion initiated; parasites 41-44h old). Parasites were incubated with drug or DMSO for
8h, then assessed by thin smear. The experiment was performed twice, with similar results in
each. Representative images from one experiment are shown.
Microscopy
Parasites monitored by thin smear were dyed using Harleco Hemacolor stains (MilliporeSigma).
Images were taken using a Zeiss Axio Observer.D1 at the Washington University Molecular
Microbiology Imaging Facility. For transmission electron microscopy, infected RBCs were fixed
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in 2% paraformaldehyde/2.5% glutaraldehyde (Polysciences Inc., Warrington, PA) in 100 mM
sodium cacodylate buffer, pH 7.2 for 1 hour at room temperature. Samples were washed in
sodium cacodylate buffer at room temperature and post-fixed in 1% osmium tetroxide
(Polysciences Inc.) for 1 hour. Samples were rinsed extensively in deionized water prior to en
bloc staining with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for 1 hour.
Following several rinses in deionized water, samples were dehydrated in a graded series of
ethanol and embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 95 nm were cut with a
Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained with
uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX transmission electron
microscope (JEOL USA Inc., Peabody, MA) equipped with an AMT 8-megapixel digital camera
and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques, Woburn,
MA).
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Figures
A.

B.

Figure A1.1. Architecture of pSN054 and application to editing PM V. Schematic of pSN054
showing restriction sites (dashed lines), loxP (red triangles), aptamers (black lollipops), and 2A
skip peptide (pink rectangle). Restriction sites allow the choice of 3x-HA (blue), FLAG (green),
or Myc (purple). An expression cassette drives production of the Tet repressor-DOZI helicase
fusion (TetR-DOZI, black), Renilla luciferase (Ren. Luc.), and blasticidin-S deaminase
selectable marker (BSD). The T7 expression cassette drives transcription of CRISPR guide
RNAs (gRNA). (B) Cloning strategy for editing of the PM V locus. Left and right homologous
regions (LHR and RHR) were inserted at FseI and I-SceI respectively, while the recoded gene
sequence was inserted into plasmid cut with AsiSI and BsiWI. The endogenous PM V sequence
was disrupted by CRISPR/Cas9 gene editing. When transcribed, aptamers are bound by TetRDOZI in the absence of aTc, repressing translation. In the presence of aTc, TetR-DOZI does not
bind the aptamers and translation occurs as normal.
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Figure A1.2. depletion of PM V demonstrates its essentiality in parasite culture. (A) Tagging was
verified by Southern blot with right homologous region (RHR) used as probe. Digest schematic
APT
shows expected size of bands. The top-most and bottom three bands in the “PM V lane are
detected in the parent as well and are likely non-specific. (B) Protein tagging was verified by
western blot using an anti-FLAG antibody as well as an antibody to a cytosolic sugar phosphatase
HAD1 as loading control. (C) Expression levels were compared to the parent strain by western blot
using anti-PM V and anti-HAD1 antibodies. An average ratio of PM V to HAD1 signal from two
experiments is shown. (D) Knockdown of PM V was initiated by washing aTc from ring-stage
cultures and adding either 500nM aTc (+aTc) or an equal volume of DMSO (-aTc). After 72 hours,
knockdown was assessed by western blot, probing with anti-PM V and anti-HAD1. Uncut gels used
to generate panels (C) and (D) are shown in Fig. S2. (E) Two separate transfected PM V-regulatable
lines (“#1” and “#2”) were split +/- aTc as above and growth monitored daily by flow cytometry.
Experiment was done twice in technical triplicate. A representative experiment is shown, with data
points representing mean and error bars standard deviation.
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Figure A1.3. PM V is maintained in substantial excess. (A) Knockdown of PM V was initiated by
washing aTc from ring-stage cultures, and parasites maintained in 500nM, 20nM, 3nM, 2nM, 1nM,
or 0nM (DMSO) aTc. Growth was monitored daily by flow cytometry. Three experiments were
performed with each sample done in technical triplicate. A representative experiment is shown
with points representing mean and error bars the standard deviation. (B) Samples were prepared
as in (A) but harvested at 72h for western blot. Three experiments were performed. A
representative blot is shown. Uncut gels are shown in Fig. S3. (C) Quantification of the three
western blots. Blue dots represent mean PM V signal relative to the 500nM signal, as quantified
on a diluted standard curve for each experiment (see Methods); bar height represents the mean of
the three experiments; error bars represent the standard error of the mean.
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Figure A1.4. PM V-depleted parasites arrest early in life cycle. (A) aTc was washed from ringstage parasites, which were then maintained in 500nM aTc (+aTc) or an equal volume of DMSO
(-aTc). Parasite growth was monitored by Hemacolor-stained thin smear. Experiment was
performed three times (B) Phenotype quantification for 0- to 4-hour rings (N = 208 parasites +aTc;
105 parasites –aTc). (C) Parasites maintained as above. At 96h, parasites were fixed, and early
ring-stage parasites visualized by transmission electron microscopy. (D) Parasites were maintained
as in (C) except schizonts were harvested at 90h following aTc washout. Scale bars represent 1
µm.
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Figure A1.5 PM V inhibition arrests parasite growth at two distinct points in the life cycle. Parasites
were synchronized to within 3 hours, then treated with 5 µM WEHI-842 for an 8-hour window
beginning either in (A) ring-stage (12 to 15 hours after invasion) or (B) early schizont (41 to 44
hours after invasion). At the beginning and end of each window, parasites were monitored by
Hemacolor-stained thin smear. Experiment was performed twice; representative images from one
experiment are shown.
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Figure S1 – Cloning schematic for pSN054. LHR, left homologous region; RHR, right
homologous region
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Figure S3 – Uncut gels used to generate Figure 3B and C. Gels for each of the experiments
described in Figure 3B and 3C. For each experiment, a dilution series was used to generate a
standard curve relating western blot signal to PM V amounts. Experimental samples are lanes 1-6.
Dilution series used to generate the curve is labelled.
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